The International Liver Congress 2018


11-15 April 2018 Paris
N. Poster
Poster title
Applicant name
  LBP-001 Long-term efficacy and safety of WTX101 in Wilson disease: Data from an ongoing extension of a phase 2 study (WTX101-201) Karl Heinz Weiss Received Received
  THU-001 Internalization of canalicular transporters in estradiol 17ß-D-glucuronide-induced cholestasis involves shift from "raft" to "non-raft" membrane domains and clathrin-mediated endocytosis Gisel S. Miszczuk Received Received
  SAT-001 miR-21 contributes to the onset and progression of liver disease through the deregulation of small intestine permeability André A. Santos Received Received
  FRI-001 A six month follow-up study to determine the clinical utility and patient acceptability of fibroelastography in detection and treatment of alcohol-related liver disease Lynn Owens Received Received
  THU-002 Different micro-environtmental factors induce proliferation, epithelial-mesenchymal transition (EMT) and senescence of primary cultures of human biliary tree stem/progenitor cells (hBTSCs), recapitulating the pathological features typical of human cholang Daniele Costantini Received Received
  SAT-002 Depletion of Paneth cells is associated with decreased portal hypertension and angiogenesis after partial portal vein ligation in mice. Mohsin Hassan Received Received
  FRI-002 Pilot study: evaluation of the role of the coordinating nurse in the management of patients with hepatocellular carcinoma and treated with chemoembolization julie devictor Received Received
  THU-003 Transcriptional repressors Zeb1 and Zeb2 regulate collagen production in drug-induced hepatic stellate cell activation in mice. Inge Mannaerts Received Received
  SAT-003 A functional metagenomics investigation of cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy Vincenza Di Gregorio Received Received
  FRI-003 Patient education results in better sustained virological response to anti-viral therapy in a high number of patients with chronic hepatitis C than conventional care François Habersetzer Received Received
  THU-004 Dechipering the role of Axin2/Lgr5+ pericentral hepatocytes Lara Planas-Paz Received Received
  FRI-004 Reliability and Validity Study of the Turkish Version of the Chronic Liver Disease Questionnaire Ferya Celik Received Received
  LBP-004 Long term outcomes of treatment with Trientine in Wilson Disease: Final results from a multicentre study in patients withdrawn from d-Penicillamine therapy Karl Heinz Weiss Received Received
  SAT-005 Iron reduction by venesection alters the gut microbiome in Haemochromatosis patients John Ryan Received Received
  FRI-005 Using healthcare professionals views to update and improve the Royal College of Nursing (RCN) Caring for people with liver disease: a competence framework to deliver quality person centred care Lynda Greenslade Received Received
  THU-005 A combined laser microdissection and proteomic analysis method for identification of liver tumors signatures Anne-Aurélie RAYMOND Received Received
  LBP-005 Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-alpha versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial) Vishal Patel Received Received
  LBP-006 PBI-4050, a potential anti-fibrotic drug, improves liver fibrosis in Alström Syndrome, an ultra-rare disease. Shanat Baig Received Received
  FRI-006 Hepatitis C treatment in prisons through a nurse-led program with telemedicine Annika Olsson Received Received
  THU-006 Identificiation of compounds targeting CD133-positive hepatogellular carcinoma while minimizing the damage on hepatocytes by phenotypic high-content screening Yeonhwa Song Received Received
  THU-007 Negative allosteric modulators of metabotropic glutamate receptor subtype 5 protect against hepatic ischemia/reperfusion injury Clarissa Berardo Received Received
  SAT-007 Does the gut play a pivotal role in the protective effect of coffee on liver damage? Antonella Rossi Received Received
  FRI-008 Is the Presence of Fat and Fibrosis a Higher Mortality Risk Factor Versus Cardiovascular Disease? Daniel Zaldumbide Received Received
  SAT-008 Intestinal microbiota significantly alters hepatic expression of energy metabolism genes in mice with acute cholestasis Sheida Moghadamrad Received Received
  SAT-009 Fecal microbiota profiles as a diagnostic biomarkers in cirrhosis and hepatocellular carcinoma and the impact of life style and nutrition Michal Safran Received Received
  FRI-009 Nurse-led Clinic for Liver Cirrhotic Patients: Effects on Health Related Quality of Life Maria Hjorth Received Received
  LBP-010 High Efficacy and Safety of Grazoprevir and Elbasvir for 8 Weeks in Treatment-Naive, non severe fibrosis HCV GT1b-Infected Patients : Interim Results of the STREAGER Study Armand Abergel Received Received
  THU-010 Demethylation increases the expression of type 3 inositol 1,4,5-trisphosphate receptor in hepatocytes Rodrigo Machado Florentino Received Received
  SAT-010 Gut microbes mediate liver fibrosis in chimeric mice with human hepatocytes persistently infected with hepatitis B virus Masaya Sugiyama Received Received
  LBP-011 A pilot study of empagliflozin for the treatment of non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus Wah-Kheong Chan Received Received
  THU-011 Correction of ATP7B Restores Its Sub-Cellular Localisation in Hepatocytes from Wilson s Disease Induced Pluripotent Stem Cells Jiayin Yang Received Received
  THU-012 Alternative splicing regulation during the course of liver disease Hualin Wang Received Received
  SAT-013 The Impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients Freya Wellhöner Received Received
  THU-013 Improving the efficacy of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator Charlotte Lee Received Received
  SAT-014 Paradoxically functioning onco-miR-155 and the tumor suppressor miR-194 consensus on PD-L1 immune checkpoint upregulation via MALAT-1 and XIST in hepatocellular carcinoma Sara Atwa Received Received
  SAT-015 Circulating NK cells in cirrhosis are hypofunctional, with an expanded inhibitory liver-homing CD56dimCD16+/- NK cell population Naveenta Kumar Received Received
  THU-015 hASCs-derived exosomes rescuing rats with acute liver failure by releasing IncRNA H19 yinpeng jin Received Received
  FRI-016 Outcomes of liver transplantation in patients with non-alcoholic steatohepatitis: high recurrence rate in ultrasound and transientelastography Ahad Eshraghian Received Received
  THU-016 A novel Akt activatorSC79 prevents lethal hepatic failure induced by Fas-mediated apoptosis of hepatocytes Wannan Chen Received Received
  SAT-017 M2 macrophage specfifc gene silencing in the liver using third generations mannose coated, siRNA-loaded nanohydrogel particles Leonard KAPS Received Received
  LBP-017 Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma Abderrahim OUSSALAH Received Received
  THU-017 New insights in Transforming Growth Factor Beta signalling pathway on tumor suppression and metastatic potential in primary liver cancer Sharon Pereira Received Received
  SAT-018 The pathogenic role of Stat2 in inflammation is independent of canonical interferon signaling and is mediated by TNFa. William Alazawi Received Received
  THU-018 Amiodarone-induced adipose tissue endoplasmic reticulum stress and lipolysis may contribute to hepatic lipid accumulation Inbal Houri Received Received
  FRI-018 Alcoholic Liver Disease Surpasses Hepatitis C Virus in 2016 to Become the Leading Indication for Liver Transplantation among Adults Without Hepatocellular Carcinoma in the United States Jennifer Wang Received Received
  LBP-019 13C-Methacetin Breath Test is a Highly Accurate Non-Invasive Point of Care test for Detecting CSPH in patients with NASH Jaume Bosch Received Received
  SAT-019 AXL-expressing monocytes indicate immuneparesis and disease severity in patients with cirrhosis Robert Brenig Received Received
  FRI-019 Among Adults with Hepatocellular Carcinoma Awaiting Liver Transplantation, Asians, Hispanics, and Patients with Nonalcoholic Steatohepatitis Have Disproportionately Lower Likelihood of Receiving Liver Transplantation Jennifer Wang Received Received
  THU-019 Effectof melatonin on the circadian clock pathway in liver fibrosis and progressionto hepatocarcinoma Bárbara González Fernández Received Received
  FRI-020 Risk factors for dropout from the liver transplant waiting list under locoregional treatment Han Ah Lee Received Received
  SAT-021 Secreted ectodomain of SIGLEC-9 and MCP-1 ameliorate acute liver failure in rats by altering bone marrow macrophage polarity Takanori Ito Received Received
  LBP-021 The percentage of patients with HCV infection in need of a liver transplant is rapidly declining while their survival after transplantation is improving: A study based on European Liver Transplant Registry. Giovanni Perricone Received Received
  FRI-021 Outcome of liver grafts procured from hepatitis C-positive donors in the era of direct-acting antiviral drugs: a preliminary single centre experience Silvia Martini Received Received
  LBP-022 Mas-related G-protein coupled receptor type D (MrgD) antagonism produces splanchnic vasculature-specific effects, leading to a large reduction in portal pressure in cirrhotic animals Lakmie Gunarathne Received Received
  SAT-022 Elevated programmed death ligand 2 (PDL2) in macrophages of BALB/c mice model of liver fibrosis associated with decreased CD80 and IL12 expressions Johnny Amer Received Received
  THU-022 Investigating the effect of adrenomedullin on hepatic NF-kB activation by 2D and 3D hepatic cell cultures Krista Rombouts Received Received
  FRI-022 Preemptive direct-acting antiviral therapy in naive or NS5A-relapser liver transplant recipients: a single centre experience Silvia Martini Received Received
  LBP-023 HCV treatment with DAA in patients listed for liver transplant does not result in an increased risk of HCC recurrence post-liver transplant Chiara Mazzarelli Received Received
  FRI-023 Donor-specific anti-HLA antibodies are not associated with non-anastomotic biliary strictures, but both are independent risk factors for graft loss after liver transplantation Bart van Hoek Received Received
  LBP-024 Increased risk of liver cancer in cirrhotic patients associated to direct acting antivirals Maria Reig Received Received
  SAT-024 Ethanol dampens IL-37 expression in liver tissue Felix Grabherr Received Received
  THU-025 Involvement of sphingosine-1P receptor 2 (S1PR2) in taurolithocholate-induced impairment of multidrug resistence-associated protein 2 (Mrp2) in rat Romina Andermatten Received Received
  SAT-025 Serum CXCL14 chemokine as a biomarker during murine acute and chronic hepatitis Christelle Devisme Received Received
  THU-026 The analysis of delta40p53, one of p53 splicing isoforms, in hepatocellular carcinoma cells. Haruhisa Nakao Received Received
  LBP-026 A structurally engineered fatty acid, icosabutate, displays optimised absorption, distribution and metabolism properties for targeting hepatic inflammation and normalises elevated liver enzymes in dyslipidemic patients David A. Fraser Received Received
  SAT-026 Autophagy-related liver enzymes in chronic liver disease Demetrious Samonakis Received Received
  LBP-027 Rifaximin reduces the incidence of sepsis and all cause admissions whilst on the liver transplant waiting list Debbie Shawcross Received Received
  THU-027 CCNT1 mediates mTor inhibitor related antiviral effects in HCV genotype 2a Alexandra Frey Received Received
  FRI-027 Incidence of waitlist removal and transplantation rates are similar in NASH, cryptogenic and autoimmune hepatitis cirrhosis Paul J. Thuluvath Received Received
  SAT-028 Clinical presentation, natural history and treatment of hepatic sarcoidosis: a case-series of 39 patients with histologically proven hepatic sarcoidosis Malte Wehmeyer Received Received
  THU-028 Cerium oxide nanoparticles protect against oxidant mediated injury and recover kinase activity of multiple pathways in human-derived hepatocellular carcinoma cells Meritxell Perramon Corominas Received Received
  FRI-028 Liver transplant waitlist mortality, transplantation rates and post-liver transplant outcomes in Hispanics Paul J. Thuluvath Received Received
  THU-029 Interaction between hepatic sinusoidalendothelial cells and monocytes modulates IL33 driven Th2 dependent liver fibrogenesis Johanna Reissing Received Received
  SAT-029 Upregulation of miR-34c driven by JNK and FOXO3 in livers expressing mutant Z alpha1-antitrypsin Pasquale Piccolo Received Received
  LBP-029 Viral integration profiles in the plasma cell-free DNA from patients with HBV infection well represent tumor clone compositions during HCC development Dake Zhang Received Received
  FRI-029 Pretransplant Karnofsky Performance Status is an independent predictor of post-liver transplant survival Paul J. Thuluvath Received Received
  LBP-030 8 weeks of ledipasvir-sofosbuvir for non-cirrhotic patients with HCV genotype 4: A single-arm multicenter phase 3b study (HepNed-001) Anne Boerekamps Received Received
  THU-031 Hypoxia strongly modulates hepcidin mRNA expression via macrophage-hepatocyte crosstalk Ines Silva Received Received
  SAT-031 Refinement of diagnostic criteria and frequency estimation of LPAC syndrome: a French multicenter study Dong Catherine Received Received
  FRI-031 The Survival Benefit of Hepatic Resection in Advanced Cases for Intrahepatic Cholangiocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis Mohamed Moustafa Received Received
  THU-032 Hypoxia enhances H2O2-mediated upreguation of hepcidin: potential role of oxidases in iron regulation Ines Silva Received Received
  FRI-032 A nomogram with sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant patients: a competing risk analysis in a national cohort Jeroen van Vugt Received Received
  SAT-032 Role of alpha-1 antitrypsin genotypes in the progression of adult liver disease Vítor Pereira Received Received
  THU-033 Reduced PI3K pathway in NK cells of F4-NAFLD patients inhibited mTOR expressions and was correlated with their impaired function Johnny Amer Received Received
  SAT-033 Genetic ablation of CHOP decreases hepatic accumulation of mutant Z alpha1-antitrypsin Sergio Attanasio Received Received
  FRI-033 Tacrolimus cumulative exposure after liver transplantation is associated with a progressive derangement of renal function despite routine dose adjustments Manuel Rodríguez-Perálvarez Received Received
  SAT-034 Etiology of splanchnic vein thrombosis in 812 chinese patients from a single center Guohong Han Received Received
  SAT-035 Step-wise strategy for Chinese Budd-Chiari syndrome patients: long-term outcome of a large scaleprospective observational cohort Guohong Han Received Received
  FRI-035 A beneficial weekend effect? Weekend liver transplantation isassociated with reduced graft and transplant failure Neil Halliday Received Received
  THU-035 Metabolic rewiring and de novo lipogenesis induced by Glucokinase expression in hepatocarcinoma cell line Vincent Lotteau Received Received
  SAT-036 Hepatic outcomes from childhood intestinal failure: a meta-analysis of 8223 patients Aureliane Pierret Received Received
  FRI-036 Long-term Post-transplant Liver Biopsies of Children: Central Perivenulitis is Associated with Circulating Donor-specific Antibodies and Tissue C4d Deposition Lara Neves Souza Received Received
  THU-036 Role ofseptin 9 in interferon gsignalling and the development of cholangiocarcinoma Daniel Zaldumbide Received Received
  THU-037 Molecular and Histological Characterization of the Pathological Events in a Model of Cirrhosis and Hepatocarcinoma María Paulette Castro-Gil Received Received
  FRI-037 DAA therapy improves early post-liver transplant survival and induces significant changes in wait-list composition Gonzalo Crespo Received Received
  THU-038 The emerging realm of morphogens in the adult liver of mice and human - a deep insight into distribution, interaction and regulation Erik Schröder Received Received
  SAT-038 Comparison between Room-Temperature Susceptometry and MRI with respect to the cell-specific detection of liver iron Johannes Mueller Received Received
  FRI-038 Long-term subclinical inflammatory lessions in liver transplant recipients Maria-Carlota Londoño Received Received
  SAT-039 Alpha1-antitrypsin augmentation therapy is associated with an improvement in liver-related parameters in patientes with severe alpha1-antitrypsin-deficiency Carolin Victoria Heimes Received Received
  THU-039 Direct and indirect hepatoprotective mechanism of CBLB502 a TLR5 agonist Nicolas Melin Received Received
  FRI-039 Utility of FDG-PET/CT in pre-transplantation workup of the potential liver recipient with hepatocellular carcinoma Sang young Yi Received Received
  FRI-040 Long-term outcome of donor biliary complications following living donor liver transplantation Hyun Young Woo Received Received
  SAT-040 Impact of acute hepatic porphyrias on quality of life and work loss: an analysis of EXPLORE natural history study Sonalee Agarwal Received Received
  THU-040 Towards understanding the mechanisms of chlorpromazine- induced hepatic toxicity using a human HepaRG- based model. Joanna Brzeszczynska Received Received
  SAT-041 Trends in healthcare utilization in the United States and Europe associated with patient with acute hepatic porphyria with recurrent attacks in EXPLORE: a prospective, multinational natural history study of patients with acute hepatic porphyria Sonalee Agarwal Received Received
  THU-041 Uncoveringthe liver Notch code using high-throughput reporter imaging on micropatterns. Jan Mašek Received Received
  FRI-041 Impact of surgical margin according to AFP ratebefore hepatectomy for hepatocellular carcinoma Daniel Zaldumbide Received Received
  FRI-042 Upper limb lean mass by Dual Energy Xray Absorptiometry is associated with increased mortality in men with advanced cirrhosis Marie Sinclair Received Received
  SAT-043 The effect of re-exposure to somatostatin analogues in patients with polycystic liver disease René van Aerts Received Received
  FRI-043 MELD dynamics predicts waitlist outcomes in patients awaiting liver transplantation Bo Hyun Kim Received Received
  SAT-044 The PR interval in the fetal electrocardiogram is significantly prolonged in severe Intrahepatic Cholestasis of Pregnancy and potentially normalised by UDCA therapy Tharni Vasavan Received Received
  SAT-046 quantitative and qualitative lymphocyte alterations in patients with autoimmune hepatitis: what is the clinical relevance? Amédée Renand Received Received
  THU-047 Interim evaluation and projected impact of the hepatitis C virus elimination program in Georgia Josephine Walker Received Received
  SAT-047 High caloric nutrition promotes hepatocellular damage and steatohepatitis in Wilson disease rats via amplified mitochondrial damage. Claudia Einer Received Received
  FRI-047 Multi-frequency bioelectrical impedance output correlates to liver disease severity, nutritional status and functional capacity Jane Foo Received Received
  SAT-048 The natural course of FIC1 deficiency and BSEP deficiency: initial results from the NAPPED-consortium (NAtural course and Prognosis of PFIC and Effect of biliary Diversion). Daan van Wessel Received Received
  FRI-048 Pregnancy Outcomes and Reproductive Health After Liver Transplantation Christina Lindenmeyer Received Received
  THU-048 Protective effect of cannabis and coffee consumption on HCV-related mortality in French HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort) Maria Patrizia Carrieri Received Received
  SAT-049 Mild iron overload in homozygous carriers of the alpha1-antitrypsin PiZ variant is not a major driver of liver fibrogenesis Nurdan Guldiken Received Received
  FRI-049 Is a telehealth-to-home group lifestyle intervention a feasible and safe option for specialist liver clinics? Ingrid Hickman Received Received
  THU-049 Treatment of Hepatitis C in dedicated homeless GP practice by a multidisciplinary team Katherine Davidson Received Received
  THU-050 Comorbid disease burden in patients with primary liver pathologies- data from a Comprehensive Analysis of Serial Transient Elastography and other Liver disease Evaluations at the Toronto Liver Centre (CASTLE-TLC) Kerstina Boctor Received Received
  SAT-050 Compound library screening for the identification of a new treatment for polycystic liver disease Liyanne van de Laarschot Received Received
  FRI-050 Pre-Liver Transplant Visceral Adipose Tissue Predicts the Early Development of Metabolic Syndrome Post Transplant. Aidan Woodward Received Received
  THU-051 Patient monitoring of changes in the European policy response to viral hepatitis C treatment: Hep-CORE findings from 2016 to 2017 Jeffrey Lazarus Received Received
  FRI-051 Follow-up of non-HLA and anti-HLA antibodies: importance in graft failure after liver transplantation Speranta Iacob Received Received
  THU-052 Heterogeneity in hepatitis C virus treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access Nick Scott Received Received
  SAT-052 Transcatheter recanalization with angioplasty and/or stenting: a novel, minimally-invasive treatment option for children with chronic portal vein thrombosis with cavernous transformation Henri Justino Received Received
  FRI-052 CXCL9 and CXCL10 gene polymorphisms are associated with earlier onset of acute cellular rejection after liver transplantation Ana Ostojic Received Received
  FRI-053 Post-transplantation Outcomes in Cirrhosis secondary to Granulomatous Liver Diseases Avesh Thuluvath Received Received
  SAT-053 Clinical response after laparoscopic fenestration of large simple hepatic cysts: a systematic review L.H.P. Bernts Received Received
  THU-054 The time trend of proportion and mortality rate of admissions associated with acute respiratory illness in cirrhotic patients with diverse ethnicity and socioeconomic status: an analysis on the U.S. National Inpatient Sample Donghak Jeong Received Received
  FRI-055 99mTechnetium-MebrofeninHepatobiliary Scintigraphy predicts portal hypertension in Child-Pugh Acirrhosis Thiery Chapelle Received Received
  THU-055 The cost-effectiveness of needle and syringe provision in preventing transmission of Hepatitis C virus in people who inject drugs Zoe Ward Received Received
  FRI-056 Chronic Rejection in Children: Risk factors, Diagnosis and Outcome Tamir Miloh Received Received
  THU-057 Quantifying the Impact of Achieving the World Health Organization (WHO) Global Health Sector Strategy (GHSS) Goals for Hepatitis C in the EURO Region Sarah Robbins Received Received
  THU-058 Quantifying the Impact of Achieving the World Health Organization (WHO) Global Health Sector Strategy (GHSS) Goals for Hepatitis C in the African Region Sarah Robbins Received Received
  SAT-058 The Galactose Elimination Capacity test may monitor treatment response and disease progression in patients with Wilson Disease Thomas Damgaard Sandahl Received Received
  FRI-058 Stabilization of acute-on-chronic liver failure patients before liver transplantation predicts post-transplant survival. Peter Huebener Received Received
  THU-059 Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the "underwater portion of the iceberg" matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? Sarah Robbins` Received Received
  SAT-059 The global prevalence of lysosomal acid lipase deficiency estimated by meta-analysis of pathogenic mutations and functional variants from next-generation sequencing data Anna Carter Received Received
  FRI-059 High mortality after liver transplantation for cirrhotic patients with previous spontaneous peritonitis occurring within one year prior to transplantation Mayada Elnegouly Received Received
  SAT-061 Liver disease in a cohort of patients with Gaucher disease from Southern Brazil: a cross-sectional study. Rodrigo Starosta Received Received
  THU-061 Improved Health Outcomes fromHepatitis C Treatment Scale-Up in Spain´s Prisons: A Cost-Effectiveness Study Jagpreet Chhatwal Received Received
  FRI-061 Donor liver small droplet macrovesicular steatosis is associated with reduced graft survival after liver transplantation Flaminia Ferri Received Received
  THU-062 Poor awareness of liver disease shortly before cirrhosis death: findings from a large community cohort in the UK Hamish innes Received Received
  SAT-062 Characteristics associated with non-response to ursodeoxycholic acid in primary biliary cholangitis Teresa Dias Received Received
  FRI-062 Liver transplantation in HIV patients: a descriptive cohort study Sara Castelo Branco Received Received
  THU-063 Eradicate Hepatitis C: a pilot of treatment as prevention in active drug users Jasmine Schulkind Received Received
  SAT-063 Evaluation of the New criteria in the diagnosis of cystic fibrosis liver disease Ilianna Mani Received Received
  THU-064 HIV co-infection is associated with increased liver complications and reduced mental health among patients with chronic hepatitis B Mei Lu Received Received
  SAT-065 Transient elastography as a screening method for chronic liver disease in apparently healthy population. Results from de ETHON cohort. Elba Llop Received Received
  THU-065 Australia on track to achieve WHO elimination targets following rapid initial DAA treatment uptake Jisoo Amy Kwon Received Received
  FRI-066 Inducible ablation of TGFß receptor type 2 limited to hepatic stellate cells potently inhibits liver fibrosis and attenuates inflamation Olena Molokanova Received Received
  SAT-066 Prognostic Value of 2D-Shear Wave Elastography(2D-SWE) for staging cirrhosis in chronic liver diseases (CLD) in two severity classes according to liver-related complications Priscila Pollo-Flores Received Received
  THU-067 Achieving World Health Organization targets for hepatitis B by 2030: Results from 17 WHO AFRO Countries Helen Nde Received Received
  SAT-067 Reliability criteria for liver stiffness measurement with ARFI Jerome Boursier Received Received
  FRI-067 Caspase-8 is a gender-specific modulator of chronic cholestatic liver disease in female Mdr2 knockout mice. Julia Jung Received Received
  SAT-068 The ProC3 marker of type III collagen formation accurately reflects hepatic inflammation and fibrosis stage in asymptomatic alcoholic liver disease patients Maja Thiele Received Received
  THU-068 Achieving World Health Organization targets for hepatitis B in infants and 5-year olds by 2030: Results from 17 WHO AFRO countries Helen Nde Received Received
  FRI-068 Novel pro-fibrotic properties of macrophage migration inhibitory factor in non-alcoholic steatohepatitis is associated with a shift in natural killer T cell populations Daniel Heinrichs Received Received
  FRI-069 High density lipoproteins production induced by selective intestinal LXR activation protects against the progression of liver injury by shifting M1 to M2 Kupffer cell phenotype. Irene Pierantonelli Received Received
  THU-069 Impact of the hepatitis B vaccine birth-dose on perinatal incidence between 2017-2050: Results from 17 WHO AFRO Countries Helen Nde Received Received
  SAT-070 Liver stiffness measurement predicts short-term liver related-morbidity of allogeneic hematopoietic stem cell transplantation Thomas Karlas Received Received
  FRI-070 Increased expression of pregnancy-associated plasma protein-A in activated hepatic stellate cells is a potential therapeutic target and serum marker of hepatic fibrosis Freese Kim Received Received
  THU-071 The ENABLE projects: Consistent high prevalence of undiagnosed active blood borne virus infection [HBV, HCV, HIV] across four urban emergency departments in England. - Data for action? Mark Hopkins Received Received
  FRI-071 Oncostatin M regulates the role of macrophage during progression and resolution of hepatic fibrosis Michitaka Matsuda Received Received
  SAT-071 Liver stiffness measurement by 2D SWE from General Electric is similar with Transient Elastography in clinical significant portal hypertension diagnosis Rusu Corina Received Received
  SAT-072 Controlled Attenuation Parameter reflects intrahepatic fat content in patients with compensated advanced chronic liver disease Rosangela Piccinni Received Received
  THU-072 Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general population Jelle Koopsen Received Received
  FRI-072 Selective NDRP1 E3 ubiquitin ligase overexpression in inflammatory macrophages using functionalized carbon nanoparticles promotes fibrosis regression in cirrhotic mice Pedro Melgar-Lesmes Received Received
  FRI-073 Platelet c-type lectin-like receptor reduces cholestatic liver injury in mice suguru maruyama Received Received
  FRI-074 AXL increase in NASH patients and anti-fibrotic efficacy of AXL inhibition in experimental NASH Anna Tutusaus Received Received
  THU-074 Scale-up of the national HCV screening and treatment program in Indonesia: data from Jakarta, West Java and Central Java Atiek Anartati Received Received
  SAT-074 Usefulness of liver stiffness measurement by transient elastography (TE) for predicting complications in patients with alcoholic liver disease Ana Gomez Received Received
  SAT-075 Evaluation of Multiparametric MRI in comparison with MR Elastography in patients evaluated for chronic liver disease Stephen Bravo Received Received
  THU-075 Hepatitis C screening within the National Elimination Program in the country of Georgia Ana Aslanikashvili Received Received
  FRI-075 Platelet-derived growth factor receptor alpha deprived hepatocytes attenuate thioacetamide induced liver fibrosis in mice JUNG IL LEE Received Received
  SAT-076 Glomerular filtration rate evaluation in patients with cirrhosis, which equation shall be used in clinical daily practice? Sofia Monteiro Received Received
  THU-076 Inferring the migration routes of hepatitis C virus subtype 1a lineages identifies a need for pan-European prevention strategies Lize Cuypers Received Received
  THU-077 Outcomes of hepatitis C testing, linkage to care, and treatment in a community based program in high versus low prevalence sites Lora Magaldi Received Received
  SAT-077 Predictions from a very hard liver: the role of liver stiffness in alcoholic hepatitis Fischer Petra Received Received
  SAT-078 Soluble serum vascular adhesion protein (sVAP)-1: a new biomarker in primary sclerosing cholangitis? Francesca Saffioti Received Received
  FRI-078 Non-invasive Phenotyping of Hepatic Fibrosis using Unsupervised machine Learning Yuta Nakano Received Received
  THU-078 Testing and linkage to care outcomes in baby boomers versus young adults tested in the community and linked to care at a Federally Qualified Health Center in the US Lora Magaldi Received Received
  THU-079 The impact of EMR modification and a multi-disciplinary care team on the hepatitis C care cascade of a US Federally Qualified Health Center Lora Magaldi Received Received
  SAT-079 Comparison of twelve noninvasive liver reserve models in HCC patients undergoing resection Shu Yein Ho Received Received
  THU-080 Identifying patients with cirrhosis at high risk of readmission: a population-based data-linkage Australian study Patricia Valery Received Received
  SAT-080 Enhanced Liver Fibrosis (ELF) Test predicts liver-related outcomes in postmenopausal women with risk factors in the community Paul Trembling Received Received
  FRI-080 Human amnion epithelial cells reduce liver fibrosis via effects on macrophages phenotype and liver progenitor cells in murine liver injury majid alhomrani Received Received
  SAT-081 Correlation between controlled attenuationparameter assessed with Fibroscan and steatosis percent objectively quantifiedfrom the entire liver biopsy specimen using a computer analysis tool. Preliminary results. Monica Lupsor-Platon Received Received
  THU-081 The role of a template-based assessment letter in the continuing education of general practitioners: a qualitative exploration of NAFLD educatioin Patricia Valery Received Received
  SAT-082 Performance of shear-wave elastography to detect high-risk esophageal varices in cirrhosis is improved by spleen stiffness estimation Seong Hee Kang Received Received
  FRI-082 Zoledronic Acid suppresses tumour associated macrophages andmyeloid derived suppressor cells in murine HCC Misbah Aslam Received Received
  FRI-083 Rapamycin and Zoledronic acid exert a potent antifibrotic effect in murine biliary fibrosis Misbah Aslam Received Received
  SAT-083 Non-invasive estimation of hepatic fibrosis and steatosis: comparison of 2D shear-wave elastography and acoustic structure quantification with transient elastography and controlled attenuation parameter Valentin Blank Received Received
  SAT-084 CT-driven Model for End-Stage Liver Disease: Comparison of Survival Prediction with MELD score Ji Eun Lee Received Received
  THU-084 Is macro-elimination of HCV infection the right approach for Canada? Julie Holeksa Received Received
  FRI-084 EDP-305, a highly selective and potent farnesoid X receptor agonist, favorably regulates the expression of key fibrogenic genes in vitro and in vivo Lijuan Jiang Received Received
  SAT-085 Non invasive assessment of liver fibrosis by three different Shear Wave Techniques: Head-to-Head Performance Sebastiana Atzori Received Received
  THU-085 Low rates of prenatal testing for hepatitis B and C infections in Ontario, Canada Mia Biondi Received Received
  THU-086 Scale up of hepatitis C virus treatment in the era of all-oral direct-acting antivirals (DAAs): a 9-year Greek cohort study. Vasilios Papastergiou Received Received
  FRI-086 Possible liver regeneration and anti-fibrogenic effect of NOTCH1 selective inhibitor in the diseased liver model Mitsuteru Kitade Received Received
  THU-087 Design and cost effectiveness of a hepatitis C virus elimination strategy based on an updated epidemiological study (ETHON cohort) Antonio Cuadrado Received Received
  SAT-087 Comparison of T2* and Signal Intensity Ratio Methods for MRI Assessment of Hepatic Iron Overload Christopher Kagay Received Received
  THU-088 Hepatitis C infection in the Pan American Health Organization Region: The current burden of disease and a road map for achieving the WHO Global Health Sector Strategy Goals Jonathan Schmelzer Received Received
  SAT-088 Serum biomarker usein decentralized care sites to overcome liver assessment barriers in patientswith chronic hepatitis C and HIV co-infection anne Loarec Received Received
  FRI-088 During the progression of liver fibrosis, myofibroblasts develop endoplasmic reticulum stress that both decreases their proliferation and increases their pro-angiogenic activity Axelle Cadoret Received Received
  THU-089 }The current and future disease burden of hepatitis B in the general population and among five year olds in the Eastern Mediterranean Region Jonathan Schmelzer Received Received
  SAT-089 Normal liver elasticity values in a healthy population, by age and gender, for two novel elastography systems Anesa Mulabecirovic Received Received
  SAT-090 Detection of Hereditary Haemochromatosis in the clinic and community using standard haematological tests: a comparison with iron studies Nancy Whalen Received Received
  FRI-090 Performance of quantitative collagen parameters for assessing longitudinal non-advanced liver fibrosis Yan WANG Received Received
  SAT-091 Evolving diagnostic pathways in liver disease: using quantitative magnetic resonance imaging to distinguish parenchymal and biliary disease. Katherine Arndtz Received Received
  THU-091 Modelling the impact and efficiency of screening and treatment scale-up for hepatitis C virus in Pakistan: Working towards elimination Aaron G. Lim Received Received
  FRI-091 RNA-sequencing analysis of biopsies from chronic liver disease patients identifies gene signatures associated with progressive liver disease Divya Ramnath Received Received
  SAT-092 Non invasive diagnostic approach for screening and grading of portal hypertension in patients with advanced liver disease. Sergii Kozlov Received Received
  FRI-092 Interference of PTTG1 mRNA dramatically reduces portal hypertension and liver fibrosis in fibrotic rats. Silvia Carvajal Restoy Received Received
  THU-092 Characteristics and outcomes of patients with late presentation of hepatitis B among newly-diagnosed hepatocellular carcinoma : A national cohort study 2002-2013 Dong Hyun Sinn Received Received
  THU-093 Evaluation of the Xpert Fingerstick HCV Viral Load assay François Lamoury Received Received
  SAT-093 Circulating micro-ARNs as biomarkers of alcohol liver disease and hepatocellular carcinoma Charles-Antoine PAPILLON Received Received
  FRI-093 Direct fibrosis markers kinetic in patients undergoing antiviral treatment with DAA for chronic hepatitis C Chiara Mazzarelli Received Received
  THU-094 Sero-prevalence of Hepatitis B surface antigen among 5-7 years old children and their mothers in Cambodia by nationwide multi-stage stratified random sampling strategy Junko Tanaka Received Received
  SAT-094 Liver function assessment using magnetic resonance imaging with gadoxetic acid administration Christina Levick Received Received
  FRI-094 SWAVE: Steady State Shear Wave Elastography for Fibrosis Evaluation in Liver Disease Caitlin Schneider Received Received
  SAT-095 Platelet and spleen volume criteria exclude more oesophageal varices needing treatment than Baveno VI criteria with 100% sensitivity Christina Levick Received Received
  THU-096 Khat chewing increases the risk for developing chronic liver disease: a hospital-based case-control study stian orlien Received Received
  FRI-096 AGAP2, a new player in TGF-beta signalling Amaia Navarro-Corcuera Received Received
  SAT-097 Using Wisteria floribunda agglutinin-positive Mac2-binding protein in combination with the FIB-4 index to predict significant liver fibrosis Tomi Jun Received Received
  THU-097 The Global Prevalence of HBsAg by Age in 2016 and the Case for Universal Treatment in Low and Middle Income Countries Daniel Zaldumbide Received Received
  FRI-098 Establishment of an ex vivo model of human fibrotic liver slices culture: characterization of intrahepatic immune cells and TH17 cytokines Daria Kartasheva Received Received
  SAT-099 Distribution and changes of FIB-4 index in normal health checkup examinees Shuhei Hige Received Received
  THU-099 Lowering the upper limit of serum alanine aminotransferase levels may detect significant liver disease in the elderly Hemda Schmilovitz-Weiss Received Received
  FRI-099 Endocannabinoid system contributes to activation of neutrophils in mouse chronic liver injury Liying Li Received Received
  SAT-100 Which is the chance for type 2 diabetes patients to develop severe liver disease? Ioan Sporea Received Received
  FRI-100 Exosomes secreted by the hepatocytes can inhibit and reverse hepatic stellate cells stimulation Michal Safran Received Received
  THU-100 Hepatitis C (HCV) patients with HIV co-infection demonstrate unique liver-related complications and health behaviors compared to HCV mono-infected patients Stuart C Gordon Received Received
  THU-101 Progress toward hepatitis C virus elimination through provision of care and treatment services, Georgia, 2015-2017 David SERGEENKO Received Received
  SAT-101 Intelligent Liver Function diagnostic pathway - Relevance of alanine transaminase normal values. Emma Robinson Received Received
  THU-102 High prevalence of hepatitis delta virus in specimens from Cameroon Mary Rodgers Received Received
  FRI-102 25(OH) D3 alleviate liver NK cytotoxicity in early but not in late fibrosis model of Balb/c mice due to modulations in vitamin D receptor Johnny Amer Received Received
  FRI-103 Role of the protein tyrosine kinase Mer (MerTK) in the cross-talk between macrophages and hepatic stellate cells Mirella Pastore Received Received
  FRI-104 PBI-4547 decreases hepatic stellate cell activation via AMPK signaling pathway, and reduces fibrosis in carbon tetrachloride (CCL4)-induced hepatic fibrosis model. François Sarra-Bournet Received Received
  THU-104 The first result from the general population hepatitis screening in Mongolia: 38% of 40-65 year olds screened and anti-HCV prevence of 15.6% among 40-65 year olds Bekhbold Dashtseren Received Received
  SAT-104 Phenotypic characteristics and improvement of liver stiffness measurement during follow-up in patients with Wilson s disease Razvan Iacob Received Received
  SAT-105 IsFood-intake a Confusing Factor For Liver Stiffness Evaluation by2D-SWE in Normal Subjects? Alina Popescu Received Received
  THU-105 Diagnosis of hepatitis C virus infection in Spain. On the correct side of the road? Federico Garcia Garcia Received Received
  FRI-105 the wrong or "right" effects of HCV on cardiac function in patients with low-mild liver fibrosis: a case-control study Andrea Dalbeni Received Received
  SAT-106 Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients Elton Dajti Received Received
  THU-106 HepCARE: A tool enabling the identification, assessment and management of viral hepatitis. An integrated approach to the patient journey Benjamin Anthony Received Received
  THU-107 A tool to measure the impact of inaction towards elimination of hepatitis C virus: A case study in Germany Markus CORNBERG Received Received
  FRI-107 Primary human HSC cell phenotype is differentlyregulated by pro-fibrogenic and pro-inflammatory stimuli in cirrhotic andhealthy human liver 3D ECM scaffolds Krista Rombouts Received Received
  THU-108 Linkage to HCV Care and Reincarceration Following Release from New York City Jails Matthew Akiyama Received Received
  FRI-108 Integrin avß6-targeted Near-Infrared/Positron Emission Tomography Contrast Agent for Liver Fibrosis Imaging Yong Ook Kim Received Received
  THU-109 Impact of elevated coffee intake on the risk of advanced liver fibrosis in HIV-HCV co-infected patients of the French ANRS CO13 HEPAVIH cohort: a sex-based analysis Issifou YAYA Received Received
  THU-110 High agreement with HCV RNA in screening and DAA treatment monitoring indicates that cost-effective HCV core Ag test can also be enlisted in the fight to eliminate hepatitis C Nazibrola Chitadze Received Received
  THU-111 Elimination of Hepatitis C in two different Swiss Regions - A Model-Based Microelimination Scenario Urs Rusch Received Received
  FRI-111 Glycosyltransferase GLT25D2 acts as a negative regulator of autophagy to promote acetaminophen-induced hepatotoxicity Feng Ren Received Received
  SAT-111 An effective defatting cocktail to reduce liver graft steatosis before transplantation Lynda Aoudjehane Received Received
  FRI-112 Generation of a unique liver progenitor cell gene signature to identify LPCs and LPC activation in chronic liver diseases Stefaan Verhulst Received Received
  SAT-112 A merged protocol of hypothermic oxygenated machine perfusion and normothermic machine perfusion optimises the reconditioning of marginal donor livers Yuri Boteon Received Received
  THU-112 Role of physician specialties to close gaps in the care cascade of hepatitis C: Evidence from paid claims in the United States from 2010 to 2016 Yuri Sanchez Received Received
  THU-113 Effectiveness of hepatitis C virus [HCV] screening laws in United States [US]: Evidence from paid claims data from 2010 to 2016 Yuri Sanchez Received Received
  SAT-113 The effectiveness of a pharmacological intervention for defatting of primary human hepatocytes and its effect on other cell types ofthe liver: a precursor in-vitro study to the defatting of steatotic humanlivers using normothermic machine perfusion Yuri Boteon Received Received
  FRI-113 Osteopontin might be a central regulator of inflammation during postoperative liver regeneration in humans David Pereyra Received Received
  THU-114 Development of a clinical prediction score for targeted hepatitis C screening in a low-risk HIV cohort in Cambodia Anja De Weggheleire Received Received
  FRI-114 Obeticholic acid improves fetal hypercholanaemia during cholestatic gestation Vanessa Pataia Received Received
  SAT-115 Establishing a porcine model of small for size syndrome following liver resection Mohammad Golriz Received Received
  THU-115 The hepatitis C continuum of care among HIV infected individuals in the Icona study network Antonella d´Arminio Monforte Received Received
  FRI-115 In vivo functional genetics for liver regeneration and disease Viktoriia Iakovleva Received Received
  THU-116 One-step diagnostic strategy of viremic hepatitis C virus infection from dried-blood spots: feasibility and usefulness in people who inject drugs Verónica Saludes Received Received
  SAT-116 Induction of beta-catenin in embryonic stem cell-derived dendritic cells alleviates liver damage in mouse liver inflammatory injury BIBO KE Received Received
  FRI-116 Differentiation of human pluripotent stem cells into hepatocytes is more efficient in spheroids than in 2D culture Messina Antonietta Received Received
  THU-117 The contribution of injecting drug use to Hepatitis C virus transmission globally, regionally, and at country level: a modelling study Adam Trickey Received Received
  SAT-117 Sealant pathology Omid Ghamar Nejad Received Received
  FRI-117 Hepatic autophagy potentiates ureagenesis and its enhancement protects against acute and chronic hyperammonemia Leandro Soria Received Received
  SAT-118 Preoperative biliary drainage reverses cholestasis-associated inflammatory and fibrotic gene signatures in patients with perihilar cholangiocarcinoma Rowan van Golen Received Received
  THU-118 Comparing the prevention gains of different treatment strategies at the global, regional, and country level: a modelling study Adam Trickey Received Received
  FRI-119 Liver biopsy derived induced pluripotent stem cells provide unlimited supply for the generation of hepatocyte-like cells. Diego Calabrese Received Received
  THU-120 Mass screening for hepatitis B and C in South Upper Egypt: lessons learned from a real life experience Mahmoud Elzalabany Received Received
  FRI-120 Mechanisms of action of cortisol in steatotic and non-steatotic livers subjected to partial hepatectomy with vascular occlusion Esther Bujaldon Received Received
  THU-121 Track,Trace & Treat: Results from a retrieval strategy to identify lost to follow-up chronic hepatitis C patients Isabelle Munsterman Received Received
  FRI-121 Double resin casting micro computed tomography (DUCT) of biliary and vascular system Simona Hankeova Received Received
  THU-122 Community interventions and peer support for active case finding and treatment support for underserved populations with hepatitis C in the UK, Ireland, Romania and Spain as part of the HEPCARE programme julian surey Received Received
  SAT-122 Distinct functions of phosphorylated and un-phosphorylated STAT1 in hepatocellular carcinoma Buyun Ma Received Received
  FRI-122 Human skin-derived precusor cells: a potential source for cellular therapy of the liver Joery De Kock Received Received
  THU-123 Virological and clinical characterization of a hepatitis A outbreak in Barcelona involving primarily men who have sex with men sergio Rodríguez-Tajes Received Received
  FRI-124 Bile duct organogenesis using ECM micropatterning Mazari-Arrighi Elsa Received Received
  SAT-124 Nrf2 pathway plays an important role in the development of hepatocellular carcinoma: the gene expression signature of Nrf2 observed in a rat hepatocarcinogenesis model Carlos David López Received Received
  SAT-125 ADAR-mediated A-to-I RNA Editing in Human Hepatocelluar Carcinoma Guangqi Song Received Received
  THU-125 Increasing Access to Treatment for Hepatitis C by Vulnerable, High Risk Patients Through Community Pharmacy: the SuperDOT-C Study in Scotland Andrew Radley Received Received
  THU-126 Drug utilization in patients with liver cirrhosis in ambulatory care sander borgsteede Received Received
  SAT-126 Sulfatase 2 Antagonizes Starvation-Induced Autophagy in Hepatocellular Carcinoma Paola Romecin Received Received
  SAT-127 In vivo knockdown of Plk1 using a novel breakable mesoporous silica particle siRNA carrier reduces tumor growth in an orthotopic xenograft mouse model of hepatocellular carcinoma François H.T. Duong Received Received
  THU-127 Long-term effectiveness of Sofosbuvir-Based Hepatitis C regimens in Central and West Africa (ANRS 12342) Maël Baudoin Received Received
  FRI-127 While Hepatocellular Carcinoma (HCC) Has Become the Leading Indication for Liver Transplantation in the United States, the Probability of Receiving Liver Transplantation Among Adults with HCC Has Rapidly Declined Jennifer Wang Received Received
  THU-128 Cost-effectiveness of Sofosbuvir-Based Hepatitis C regimens in Central and West Africa (ANRS 12342) Sylvie Boyer Received Received
  FRI-128 Two new blood tests for identifying patients with chronic liver diseases, at high risk of primary liver cancer. Thierry Poynard Received Received
  THU-129 HCV screening in the adult general population of a basic health area in the Valencian Region (Spain) ANTONIO GARCIA HEROLA Received Received
  SAT-129 Hepatocyte c-Jun N-terminal kinases determine cell fate and carcinogenesis in NEMO-deficient mice Mohamed Ramadan Mohamed Received Received
  FRI-129 Contrast-enhanced ultrasound for non-invasive diagnosis of hepatocellular carcinoma: a comparison between CEUS LI-RADS and ESCULAP criteria in a large high-risk cohort of patients Antonio Saviano Received Received
  SAT-130 Chemokine receptor CXCR3 modulates polarization of tumor associated macrophages limiting tumor growth and angiogenesis in murine hepatocellular carcinoma Elisa Fabiana Brandt Received Received
  THU-130 The nature and impact of stigma in patients with chronic hepatitis B: a systematic literature review Kristien Bonroy Received Received
  FRI-130 Tumour progression and recurrence after direct acting antiviral therapy for hepatitis C in patients with previously treated or active hepatocellular carcinoma Simone Strasser Received Received
  SAT-131 Hepatocyte-derived Osteopontin drives the development of hepatocellular carcinoma Romain Desert Received Received
  THU-131 Cost-effectiveness of scaling up Hepatitis C virus prevention, testing and treatment interventions among people who inject drugs in the US Hannah Fraser Received Received
  FRI-131 Identification of keratin 19-positive cancer stem cells associating human hepatocellular carcinoma using 18F-FDGPET and CYFRA 21-1 Takayuki Kawai Received Received
  SAT-132 AAV2 viral infection in liver and tumor development Tiziana La Bella Received Received
  FRI-132 Hepatocellular carcinoma (HCC) after direct-acting antivirals (DAA) does not show differences at diagnosis compared with HCC after IFN-based treatments. Results of a national HCC Registry in Spain Carlos Rodríguez de Lope Received Received
  THU-132 HEV positivity in domesticated pigs and a relative risk of HEV zoonosis among occupationally exposed individuals in Vietnam Xuan Hoan Nghiem Received Received
  SAT-133 Sorafenib increases the percentage and cytotoxicity of circulating NK cells in hepatocellular carcinoma patients Guohong Han Received Received
  FRI-133 Regression of fibrosis stage after treatment in patients with HFE haemochromatosis and severe fibrosis at diagnosis: relevance to hepatocellular carcinoma edouard Bardou-Jacquet Received Received
  THU-133 Is HCV elimination among HIV-infected people who inject drugs possible through HCV treatment targeting HIV/HCV coinfection? A modeling analysis for Andalusia, Spain Britt Skaathun Received Received
  SAT-134 Rapamycin and Zoledronic Acid strongly inhibit growth of advanced murine hepatocellular carcinoma via activation of innate and adaptive immunity Muhammad Ashfaq-Khan Received Received
  THU-134 Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study Behzad Hajarizadeh Received Received
  FRI-134 Nonalcoholic Fatty Liver Disease is the Most Common Cause of Hepatocellular Carcinoma (HCC) in Individuals without Cirrhosis: A United States Multicenter Study Andrew deLemos Received Received
  FRI-135 Clinical effectiveness of enhanced surveillance in "super-high risk" cirrhotics as evaluated in the ITA.LI.CA. Study Group Filippo Pelizzaro Received Received
  THU-135 The French Donor Risk Index for liver transplantation: development, internal and external validation. Audrey Winter Received Received
  SAT-136 Insulin receptor isoform A is a new player in the progression of hepatocellular carcinoma Eva Benabou Received Received
  THU-136 Looking for the best matching between donor and recipient in liver transplantation: a sequential stratification approach. Audrey Winter Received Received
  FRI-136 Patterns of glutamine synthetase expression as marker of beta catenin activation in hepatocellular adenomas Christine Sempoux Received Received
  THU-137 One-year injecting frequency trajectories as predictors of hepatitis C acquisition: findings from an observational cohort study of people who inject drugs in Montréal, Canada Emmanuel Fortier Received Received
  SAT-137 Defective DNAM-1 mediated cytotoxicity in NK cells infiltrating hepatocellular carcinoma Barbara Oliviero Received Received
  FRI-137 Usefulness of newly proposed albumin-bilirubin grade and its modification -Japan nationwide survey Atsushi Hiraoka Received Received
  SAT-138 Difference of gene mutational profile among viral- and non-viral HCC with or without prior HBV infection: Results of comprehensive deep sequencing analyses of cancer genes and HBV/AAV integration Fukiko Kawai-Kitahata Received Received
  THU-138 Cost-effectiveness of elbasvir/grazoprevir + sofosbuvir for the treatment of chronic HCV genotype 3 infection in Argentina Emiliano Bissio Received Received
  FRI-138 Serological diagnosis of early HCC in NASH: A German multicenter study Jan Best Received Received
  SAT-139 Therapeutics of cell-specific MAPK modulation in chronic liver disease using (siJNK2) nanodelivery Marius Woitok Received Received
  THU-139 Molecular Epidemiology of Hepatitis B and D in the Pacific Islands of Kiribati Kathy Jackson Received Received
  FRI-139 Deviations of the immune cell lanscape between healthy liver and hepatocellular carcinoma Nataliya Rohr-Udilova Received Received
  SAT-140 Deletion of MyD88 in non-parenchymal cells, but not in parenchymal cells attenuates the progression of hepatocellular carcinoma Antje Mohs Received Received
  SAT-141 Interventional gene targeting of cell cycle regulators identifies Cyclin E1 as a suitable target for attenuating hepatocellular carcinoma progression Roland Sonntag Received Received
  FRI-141 Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance Julien Calderaro Received Received
  THU-141 Efficacy of a program based on on -site dried blood spot testing for hepatitis C to improve linkage to care and treatment uptake for people who injected drugs Dalia Morales Arraez Received Received
  SAT-142 Quantitative comparison of PD-L1 immuno-histochemical assays in hepatocellular carcinoma: the Blueprint-HCC study. David James Pinato Received Received
  FRI-142 Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20 year experience from a national programme Ibrahim Hassan Received Received
  THU-143 Screening for hepatitis C in Ontario, Canada: Exploring antibody positivity in the federal and provincial correctional systems Kinsey Beck Received Received
  SAT-143 Mixed HCC-ICC Liver Cancer Derives From Hepatic Progenitor Cells- a Lineage Tracing Investigation in Mouse Liver Inflammation Models nofar rosenberg Received Received
  FRI-143 Prospective evaluation of gadoxetic-acid MR for the non-invasive diagnosis of hepatocellular carcinoma in newly detected nodules <=2 cm in cirrhotic patients Alejandro FORNER Received Received
  SAT-144 Circulating exosomal non-coding RNAs as prognostic biomarkers in human hepatocellular carcinoma Yu Rim Lee Received Received
  THU-144 Can HCV be eliminated among HIV-infected MSM in Berlin? Modeling a setting with increasing incidence and high treatment rates. Patrick Ingiliz Received Received
  FRI-144 Risk of early de-novo hepatocellular carcinoma (HCC) in patients with genotype-1b HCV compensated cirrhosis treated with 3 direct-acting antivirals (DAAs) - a real life, multicenter study Cristina-Maria Muzica Received Received
  FRI-145 Incidence of HCC in TIPS bearing cirrhotic patients. José Manuel Garcia-Ortiz Received Received
  THU-145 Hepatitis C elimination by 2030 is feasible in Brazil: a mathematical modelling aproach Maria Cassia Mendes Correa Received Received
  THU-146 Micro-elemination of hepatitis C among patients with congenital bleeding disorders in Slovenia Mojca MATICIC Received Received
  SAT-147 In-vivo validation of cancer genes using liver organoids Anna Saborowski Received Received
  THU-147 Hepatitis E in pigs in Israel: seroprevalence, molecular characterization and potential impact on humans Orna Mor Received Received
  SAT-148 Activated platelets contribute to the progression of hepatocellular carcinoma by altering the immune cell environment Natasa Pavlovic Received Received
  FRI-148 Gp38+ hepatic progenitor cell-derived large extracellularvesicles in biliary cancers - a novel liquid biopsy marker? Sabine Urban Received Received
  SAT-149 Polyploidy and chromosomal instability correlates with proliferative traits and lack of immune-related gene signatures in hepatocellular carcinoma Laia Bassaganyas Received Received
  FRI-149 Recommendations for the management of women with suspected hepatocellular adenoma and childbearing potential Marcia Gaspersz Received Received
  FRI-150 Preoperative van Willebrand factor is a predictor for early recurrence and overall survival in patients undergoing liver resection for oncological entities Patrick Starlinger Received Received
  SAT-150 Tumor-stroma crosstalk enhances Reg3A expressions that drives the progression of hepatocellular carcinoma Yuri Cho Received Received
  THU-151 Results of the Phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib andpravastatin vs best supportive care for the palliative treatment of HCC inCHILD B cirrhotic patients Jean-Frédéric Blanc Received Received
  SAT-151 Inhibition of YAP activation induces cell senescence and autophagy while blocking cell proliferation in cholangiocarcinoma (CCA) Massimiliano Cadamuro Received Received
  FRI-151 Treatment and prognosis of hepatic epithelioid hemangioendothelioma based on SEER data analysis from 1973 to 2007 Soon Sun Kim Received Received
  FRI-152 The validity of serum midkine, dickkopf-1 and alpha-L-fucosidase as surrogate biomarkers for the diagnosis of hepatocellular carcinoma Mariam Zaghloul Received Received
  THU-152 Systematic review and metanalysis establish dermatologic adverse events as a positive predictor of survival in hepatocellular carcinoma patients treated with sorafenib Alvaro Diaz-Gonzalez Received Received
  THU-153 Comparison of the prognosis between non-viral HCC and viral HCC Kenta Takaura Received Received
  SAT-153 Peribiliary glands and biliary tree stem cells are involved in the pathogenesis of cholangiocarcinoma arising in patients affected by primary sclerosing cholangitis Diletta Overi Received Received
  FRI-153 The impact of platelets on patients with hepatocellular carcinoma Bernhard Scheiner Received Received
  THU-154 Risk-stratified management of advanced hepatocellular carcinoma (HCC) David James Pinato Received Received
  FRI-154 Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma: A Population-Based Study Wei-Yu Kao Received Received
  THU-155 A novel post-surgical prognostic system for colorectal liver metastases treated by preoperative systemic treatment, using tumoral and non tumoral pathological changes, Ras mutation and immunoscore Pamela Baldin Received Received
  SAT-155 Mitochondrial VDAC1 based peptide as a new therapeutic agent for hepatocellular carcinoma srinivas pittala Received Received
  FRI-155 Virologic control increased overall survival after radiofrequency ablation of hepatocellular carcinoma developed on hepatitis related cirrhosis Manon Allaire Received Received
  SAT-156 The role of Lysyl oxidase in tumor microenvironment of primary liver cancer Monika Lewinska Received Received
  THU-156 Towards personalised approach in systemic treatment for hepatocellular carcinoma. The value of AGT M235T gene polymorphism Maria Reig Received Received
  FRI-156 Clinical and biological features according to fibrosis of HBV related HCC in a Western country Manon Allaire Received Received
  SAT-157 The anti-inflammatory receptor TREM2 halts the generation of HCC in mice through the inhibition of liver inflammation and hepatocyte proliferative responses María Jesús Perugorria Received Received
  FRI-157 HIV infection adversely influences the natural history of untreated hepatocellular carcinoma (HCC) David James Pinato Received Received
  THU-157 A statistical model for survival risk prediction in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment Sarah Berhane Received Received
  THU-158 The ALBI and p-ALBI grades predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization (TACE) Claudia Campani Received Received
  SAT-158 Functional genomics identified actin cytoskeleton remodeling required for the hypoxia-mediated EMT: a mechanistic link of tumor size to metastasis Sen-Yung Hsieh Received Received
  FRI-158 Factors implicated in the risk of developing hepatocellular carcinoma (HCC) in patients with cirrhosis due to HCV. Implications of Sustained Virological Response (SVR) andres castaño Received Received
  THU-159 Verification of staging systems and treatment algorithms for hepatocellular carcinoma: perspectives from a Japanese field practice Sadahisa Ogasawara Received Received
  SAT-159 The HDAC inhibitorbelinostat enhances the anti-tumor efficacy of immune checkpoint inhibitors ina murine hepatocellular carcinoma model Pablo Sarobe Received Received
  THU-160 Temporal changes in recurrent incidences after curative therapies in early stage hepatocellular carcinoma Akane Kurosugi Received Received
  THU-161 The predictive role of procalcitonin for guiding use of antibiotics in HCC patients with post TACE/RFA fever Sung Bum Cho Received Received
  FRI-161 Presence of steatosis does not increase the risk of Hepatocellular Carcinoma in patients with Chronic Hepatitis B over long follow-up CHONG TEIK LIM Received Received
  SAT-162 Sensitization of cholangiocarcinoma to chemotherapy by SOX17-induced down-regulation of drug export pumps ABCC3 and AGCG2 Jose Marin Received Received
  THU-162 Combined therapy of transarterial chemoembolizatoin and stereotactic body radiotherapy versus transaterial chemoembolizatoin for < 5m hepatocellular carcinoma: A propensity score matching analysis Baek Gyu Jun Received Received
  FRI-162 Sarcopenia is not a predictor of survival or sorafenib toxicity in advanced hepatocellular carcinoma: A Dutch multicenter study Tim Labeur Received Received
  THU-163 Out of Milan criteria and worse intetion to treat results at large liver transplant center Julia Herreras López Received Received
  FRI-163 The direct comparison between 7th AJCC staging system and 8th AJCC staging system for prediction of survival with Korean multicenter HCC patients Young-Sun Lee Received Received
  SAT-163 Defective NKp30-mediated function in hepatocellular carcinoma-infiltrating NK cells STEFANIA MANTOVANI Received Received
  SAT-164 Cost-effective target sequencing panel for hepatocellular carcinoma mutational screening Charlotte Ng Received Received
  FRI-164 Serum and urine extracellular vesicles contain mRNA biomarkers for primary sclerosing cholangitis (PSC) and cholangiocarcinoma (CCA) Ander Arbelaiz Received Received
  SAT-165 Lack of Osteopontin promotes non-alcoholic steatohepatitis (NASH) and fibrosis, but protects against hepatocellular carcinoma (HCC) progression and mortality in a NASH-HCC mouse model Alexander Daniel Nardo Received Received
  THU-165 Comparision of long-term outcome for single small hepatocellular carcinoma between different treatment modalities by size and tumor marker Dong Hyun Sinn Received Received
  SAT-166 Canonical inhibition of TransformingGrowth Factor ß Receptor 1 triggers proliferation of hepatocellular carcinoma andis associated with Toll Like Receptor 7 upregulation. Fatma Mohamed Received Received
  THU-166 Multimodal and sequential treatmente for hepatocellular carcinoma: how "real-life" complies with international recommendations Michela Triolo Received Received
  SAT-167 S100a11 is part of a whole network of tumor suppressors and oncogenes deregulatedearly with hepatic steatosis and contributing to hepatocellular carcinoma development Cyril Sobolewski Received Received
  FRI-167 Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: a validation study of the HAP and SAP scores Francesco Tovoli Received Received
  SAT-168 Low density neutrophils, as immunosuppressant, increased in HCC patients, highly correlated with advanced stage, predicted stage I HCC recurrence and all patients survival Chien-Hao Huang Received Received
  THU-168 Performance of ALBI-PD Model and PALBI Grade in Sorafenib-failed Hepatocellular Carcinoma Pei-Chang Lee Received Received
  FRI-168 CD44 rs187115 gene polymorphism in cirrhotic hepatitis C patients with hepatocellular carcinoma nermeen abdeen Received Received
  SAT-169 Chemosensitizing effects of beta-caryophyllene oxide in liver cancer Silvia Di Giacomo Received Received
  FRI-169 Hepatocellularcarcinoma as second primary malignancy: exposing an overlookedpresentation of liver cancer Harrys Torres Received Received
  FRI-170 Adherence to enhanced post-treatment surveillance is associated with increased detection of early stage recurrence after radiofrequency ablation but not surgical management of hepatocellular carcinoma Yin Chan Received Received
  SAT-170 Application of patient-derived liver cancer cells for personalized treatment approach: from phenotypic characterization to therapeutic target identification Darko Castven Received Received
  SAT-171 Depletion of the HDC/histamine axis ablates tumor formation, angiogenesis, EMT and inflammation in Mdr2 knockout mice Lindsey Kennedy Received Received
  THU-172 Transarterial-chemoembolization and hepatocellular carcinoma. A regular interval approach avoids the 10% of the procedures and an optimal survival with the transition to systemic therapy in 80% of the patients Marco Sanduzzi Zamparelli Received Received
  SAT-172 High miR-224 expression in cholangiocarcinoma may predict survival Tímea Szekerczés Received Received
  FRI-172 Particularities of hepatocellular carcinoma on chronic hepatitis C in the era of all- oral antiviral treatment ELENA LAURA ILIESCU Received Received
  FRI-173 Short-term evaluation of hepatocellular carcinoma after locoregional treatment: usefulness of contrast-enhanced ultrasonography Giulia Gibiino Received Received
  THU-173 Impact of regorafenib in the clinical practice and identification of second-line treatment orphan patients Marco Sanduzzi Zamparelli Received Received
  THU-174 Combined Photodynamic Therapy with Systemic Chemotherapy Improves Survival of Patients with Irresectable Cholangiocarcinoma Maria Angeles Gonzalez-Carmona Received Received
  FRI-174 Performance of Wisteria floribunda agglutinin-positive Mac2-binding protein as an HCC biomarker in an ethnically diverse cohort of patients with chronic HBV and HCV Tomi Jun Received Received
  THU-175 Outcomes of single or sequential dual modality loco-regional therapies in Hepatocellular carcinoma Vinay Kumar Balachandrakumar Received Received
  SAT-175 The role of IL-6 signaling pathway in cholangiocarcinoma Thi Mai Ly Nguyen Received Received
  FRI-175 A functional ATG16L1 (T300A) gene variant is associated with increased risk for hepatocellular carcinoma in cirrhosis Philipp Reuken Received Received
  THU-176 Clinical features and prognosis of advanced stage hepatocellular carcinoma; verification of diverse progression processes Masayuki Yokoyama Received Received
  FRI-176 Serial Changes in Alpha-fetoprotein, Lectin-Bound Alpha-fetoprotein and Des-r-Carboxy Prothrombin in Prospectively Collected Serum Samples before the Diagnosis of Hepatocellular Carcinoma Jonggi Choi Received Received
  FRI-177 Sphingolipids: a further step into the detection of early and intermediate hepatocellular carcinoma Iuliana Nenu Received Received
  SAT-177 A new insight on the stem cell growth factor beta as astrong predictor of therapy response in hepatocellular carcinoma Riccardo Patti Received Received
  THU-177 Soluble urokinase plasminogen activator receptor (suPAR) represents a novel serum biomarker for patients undergoing resection of colorectal liver metastases Sven Loosen Received Received
  SAT-178 Disrupted cholesterol synthesis leads to female prevalent hepatocellular carcinoma in transgenic mice Kaja Blagotinšek Cokan Received Received
  THU-178 Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with Sorafenib Giulio Antonelli Received Received
  FRI-178 A high alpha-fetoprotein slope prior to therapy correlates with poor prognosis of patients with hepatocellular carcinomas. Carolin Czauderna Received Received
  THU-179 The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment Jee-Fu Huang Received Received
  THU-180 Analyses of intermediate stage hepatocellular carcinoma patients from the point of view of designing clinical trials comparing transarterial chemoembolization and systemic therapies Keisuke Koroki Received Received
  SAT-180 Sorafenib/Regorafenib resistance and BH3-mimetics efficacy in hepatocellular carcinoma treatment is determined by mitochondrial changes in the BCL-2 profile. Anna Tutusaus Received Received
  FRI-181 Clinical Presentation and Survival of Asian and Non-Asian Patients with HBV-related Hepatocellular Carcinoma (HBV-HCC): Results of 767 United States patients with long-term follow-up. Joseph Hoang Received Received
  THU-182 ALBI is an independent predictor ofsurvival in resected patients with HCC Philippe Kolly Received Received
  THU-183 Portal vein tumor thrombosis has a direct impact on liver function. Roman Klöckner Received Received
  FRI-183 Monofocal HCC: Milan Criteria or BCLC staging system? An analysis of the ITA.LI.CA. database Giulia Peserico Received Received
  SAT-183 Aspecific ECM composition regulates Smad dependent - TGFbeta1–induced EMT response in HepG2 cells engineered in cirrhotic and healthyliver 3D scaffolds Krista Rombouts Received Received
  FRI-184 Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma Sebastian Schotten Received Received
  SAT-184 Analysis of HBV DNA Integration in Tumor and non-Tumor Liver Tissues by a High-Throughput Viral Integration Detection Method. Deborah D´Aliberti Received Received
  THU-184 A Novel Model for the Outcome Prediction of Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma with or without Impaired Hepatic Function Hwi Young Kim Received Received
  SAT-185 New targets for hepatocellular carcinoma therapy: the Myc/PRMT5/RNAP II circuit Cristiana Porcu Received Received
  THU-185 Randomized trial of preoperative administration of oral pregabalin for postoperative analgesia in patients scheduled for radiofrequency ablation of focal lesions inthe liver. Sherief Abd-Elsalam Received Received
  FRI-185 Risks of Hepatocellular carcinoma and cirrhosis-associatedcomplications in patients with rheumatoid arthritis receiving biologics: a10-year population-based propensity-score matched cohort study Ching-Sheng Hsu Received Received
  SAT-186 Novel microRNA-based drug CD5-2 reduces liver cancer development in multi-drug-resistance gene-2 knockout mice Ken Liu Received Received
  FRI-186 Risk assessment of hepatocellular carcinoma in chronic liver disease patients with a combination of liver stiffness measurement and controlled attenuation parameter by FibroScan Kenichi Morikawa Received Received
  SAT-187 KRAS-dependent AKT signaling drives hepatocyte proliferation to promote tumor development in a genetic model of liver cancer Thomas Rösner Received Received
  FRI-187 Single-cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma Delia D´Avola Received Received
  THU-187 A comparison of surgical resection and transarterial chemoembolization for solitary hepatocellular carcinoma larger than 10cm: A propensity score matching analysis Hsiao-Sheng Lu Received Received
  SAT-188 The impact of the epigenetic writer LSD1in the cell cycle control in liver fibrosis and hepatocellular carcinoma Lingyu Wang Received Received
  THU-188 Phase II Trial Using Combination of TACE and SBRT for Unresectable Single Large HCC: Preliminary Report Michael Buckstein Received Received
  SAT-189 Sofosbuvir directly promotes the clonogenic capability of human hepatocellular cancer cells Jiaye Liu Received Received
  THU-190 Ubr Ubiquitin ligases as modulators of inflammation in hepatocellular carcinoma Dominique Leboeuf Received Received
  THU-191 Extrahepatic autoimmune diseases in patients with autoimmune hepatitis and their relatives: a Danish nationwide family cohort study Lisbet Grønbæk Received Received
  SAT-191 Protective effect of statins in cirrhosis might be dependent on common genetic risk variants Matthias Reichert Received Received
  FRI-191 Obeticholic acid response in primary biliary cholangitis associated with differential expression of antigen presentation, Wnt signalling and mRNA splicing Andrew L. Mason Received Received
  THU-192 Pregnancy and birth outcomes in a Danish nationwide cohort of women with autoimmune hepatitis and matched population controls Lisbet Grønbæk Received Received
  FRI-192 TGR5 modulates gallbladder function and bile acid pool composition : potential hepatoprotective impact in mice Bidault Jourdainne Valeska Received Received
  SAT-193 The mechanism of irreversibility of late stage cirrhosis Ian Wanless Received Received
  FRI-193 NLRP3 deletion leads to decreased inflammation and prevents fibrosis formation in mice after chronic bile duct ligation. Mick Frissen Received Received
  THU-193 Autoantibodies against Huntingtin-interacting protein 1-related protein are superior to conventional autoantibodies in diagnosing autoimmune hepatitis in children. Richard Taubert Received Received
  THU-194 Time Trends in Liver Transplantation for Primary Biliary Cholangitis in Europe over the Past Three Decades Maren Harms Received Received
  FRI-194 Activation of pyruvate kinase isoform M2 (PKM2)in myeloid cells protects from Concanavalin A-mediated liver injury Andrea Horst Received Received
  SAT-194 Acellular growth retardation ability (AGRA), a novel biomarker for humoral immune function, predicts the occurrence of severe bacterial infections in cirrhosis Angela Horvath Received Received
  SAT-195 Assessing Baveno VI criteria with a new point-shear wave elastography technique: the BAVElastPQ study Giulia Gibiino Received Received
  FRI-195 Carcinoembryonic antigen-relatedcell adhesion molecule 1 (Ceacam1) controls IL-2-dependent regulatory T cell induction in immune-mediated hepatitis Andrea Horst Received Received
  FRI-196 The suppressive effect of Interleukin-17-expression in antigen specific CD8+ T cells in acute experimental cholangitis in mice Stephanie Stein Received Received
  SAT-196 The efficacy and clinical outcome of transjugular intrahepatic portosystemic shunts (TIPS) in the management of ectopic variceal bleeding: a multicenter retrospective study Rosalie Oey Received Received
  THU-197 Biliary IL8 is a marker for disease progression and risk for biliary neoplasia in primary sclerosing cholangitis Martti Färkkilä Received Received
  SAT-197 Outcomes of pregnancy in women with cirrhosis - a national, population-based cohort study Hannes Hagström Received Received
  SAT-198 Prevalence and resistance rates of infections with enterococci in patients with cirrhosis Theresa Bucsics Received Received
  FRI-198 FXR Agonist Obeticholic Acid Increases Gallbladder FGF19 in Gallstone Patients Samer Al-Dury Received Received
  THU-198 Pruritus strongly reduces quality of life in PBC patients - real life data from a large national survey Andreas E Kremer Received Received
  THU-199 Functional connectivity reveals altered activation of distinct brain areas in pruritus of cholestasis Andreas E Kremer Received Received
  SAT-199 Effectiveness of "early" TIPS implantation vs "late" TIPS vs standard endoscopic treatment for acute variceal bleeding in patients with liver cirrhosis Theresa Bucsics Received Received
  FRI-199 Loss of BSEP protects MDR2/ABCB4 KO mice from cholestatic liver injury by altering bile acid profile and signaling Claudia Fuchs Received Received
  THU-200 A stepwise algorithm for biliary brush cytology shows high diagnostic performance in primary sclerosing cholangitis Erik von Seth Received Received
  FRI-200 The faecal microbiome of patients with primary sclerosing cholangitis has a characteristic signature across different geographic regions Timur Liwinski Received Received
  FRI-201 The faecal microbiome of patients with autoimmune hepatitis is characterised by reduced diversity and is different from healthy subjects and patients with ulcerative colitis Timur Liwinski Received Received
  THU-201 VCAM-1 and soluble CD-163 as novel non-invasive markers of liver fibrosis in patients with autoimmune hepatitis - a prospective study Maciej Janik Received Received
  SAT-201 The area of the paarspinal muscle mass in patients with cirrhosis although not different from controls predicts cirrhosis-associated complications and death in a large mono-centric study Cornelius Engelmann Received Received
  THU-202 Rituximab treatment experience in patients with complicated type 1 autoimmune hepatitis in Europe and North America Nwe Ni Than Received Received
  SAT-202 TLR9-mediated immune sensing of bacterial DNA in decompensated cirrhosis is stage-dependent Eihab Al-Herwi Received Received
  FRI-202 Different bile acids display distinct ability to trigger Nlrp3 inflammasome activation in a cell-dependent manner contributing to cholestatic liver injury and fibrosis Maria Inzaugarat Received Received
  SAT-203 Longitudinal outcomes of the application of non-selective beta-blockers in portal hypertension: Are low-dose non-selective beta-blockers effective? Seong Hee Kang Received Received
  THU-203 Primary biliary cholangitis in Spain: fewer symptoms and milder disease at presentation, but similar therapeutic response over the years Anna Reig Received Received
  FRI-204 A novel CCL24 blocking monoclonal antibody ameliorates liver injury in experimental models of cholestasis Adi Mor Received Received
  THU-204 Histologic Stage is a Stronger Predictor of Transplant Free Survival than APRI and FIB-4 in Patients with Primary Biliary Cholangitis Aliya Gulamhusein Received Received
  THU-205 Morning bright light treatment for sleep-wake disturbances in Primary Biliary Cholangitis (PBC) Daniel Zaldumbide Received Received
  SAT-205 Prognosis after abdominal surgery in patients with idiopathic non-cirrhotic portal hypertension: a multicenter retrospective study Laure ELKRIEF Received Received
  FRI-205 Generation of a novel mouse model for the study of autoimmune liver disease overlap syndrome Sina Fuchs Received Received
  THU-206 Novel protein biomarkers in serum extracellular vesicles for the diagnosis of primary sclerosing cholangitis (PSC) in patients with ulcerative colitis (UC) Ainhoa Lapitz Received Received
  FRI-206 Anticholestatic mechanisms of ursodeoxycholic acid in inflammatory cholestasis induced by lipopolysacharide María Valeria Razori Received Received
  SAT-206 Addition of simvastatin to standard treatment is safe, effective and improves quality of life in patients with decompensated cirrhosis Alberto Muñoz Received Received
  SAT-207 Characterization of systemic inflammatory response in hepatorenal syndrome in cirrhosis. A major role for il-6, TNF-alpha, and VCAM Cristina Sole Received Received
  FRI-207 Fine tuning of SIRT1 expression is essential to protect the liver from cholestasis Naiara Beraza Received Received
  SAT-208 Skeletal Muscle Index (SMI) Indicates Mortality Risk More Accurately than Psoas Muscle Index (PMI) in Patients with Cirrhosis. From The FLEXIT Consortium. Aldo J Montano-Loza Received Received
  FRI-208 Leukemia inhibitory factor induces cholangiocyte proliferation and corrects the impaired bile duct proliferation in sortilin-deficient mice following cholestatic injury Isabel Zvibel Received Received
  SAT-209 Loss of Subcutaneous Adipose Tissue Associates with Higher Mortality Risk in Patients with Cirrhosis Aldo J Montano-Loza Received Received
  THU-209 Differentiation of acute icteric autoimmune hepatitis from idiosyncratic drug-induced liver injury by histological and biochemical criteria Marcial Sebode Received Received
  FRI-209 Relapse of autoimmune hepatitis is associated with a low intrahepatic ratio of regulatory T cells to cytotoxic T cells prior to immunosuppression withdrawal Finn Derben Received Received
  SAT-210 Assessment of biventricular function in patients with decompensated cirrhosis and hepatopulmonary syndrome Stergios Soulaidopoulos Received Received
  FRI-210 Experimental autoimmune hepatitis in mice is associated with formation of ectopic lymphoid tissue in the liver Max Preti Received Received
  THU-210 Patients with primary biliary cholangitis exhibit reduced hippocampal volume and MRI evidence of neuroinflammation Victoria Mosher Received Received
  SAT-211 Loss of colonization resistance in cirrhosis facilitates proton pump inhibitor-associated oralization of the colonic microbiome Florian Rainer Received Received
  THU-211 Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis Carla Fiorella Murillo Perez Received Received
  THU-212 Risk factors for hepatocellular carcinoma in a large cohort of patients affected by primary sclerosing cholangitis. Francesca Saffioti Received Received
  FRI-212 Cu isotope ratio shifts in common bile duct ligated mice and correlates with the degree of cholestatic-induced liver disease Sanne Van Campenhout Received Received
  THU-213 Optimal institution of azathioprine maintenance therapy in autoimmune hepatitis: a multicenter cohort study Simon Pape Received Received
  SAT-214 The Cost-Effectiveness of Albumin in the Treatment of Decompensated Cirrhosis in Italy, Spain and Germany Paolo CARACENI Received Received
  FRI-214 The atypical antidepressant mirtazapine is hepatoprotective in a mouse model of immune-mediated hepatitis Wagdi Almishri Received Received
  FRI-215 Fine-mapping and colocalisation analysis of GWAS risk loci in Primary Sclerosing Cholangitis suggests role for proto-oncogene ETS2 in disease pathogenesis Elizabeth Goode Received Received
  THU-215 Biochemical response to ursodeoxycholic acid predicts histologic primary biliary cholangitis progression Tadashi Namisaki Received Received
  SAT-215 The role of HbA1c as a risk factor for the development of spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis Tammo Tergast Received Received
  FRI-216 Hypersensitivity and constitutive activation of the IL-12/STAT4 pathway in NK cells in Primary Biliary Cholangitis: a novel mechanism Theresa Hydes Received Received
  FRI-217 Deletion of tumor necrosis factor alpha receptor 1 leads to an increased Th17 cell response in the chronically inflamed liver Laura Berkhout Received Received
  FRI-218 Lysophosphatidic acid activates peripheral glia cells via LPA receptor 1 Katharina Wolf Received Received
  THU-218 Pre-treatment risk stratification in primary biliary cholangitis: a predictive model to guide first-line combination therapy Marco Carbone Received Received
  SAT-219 High-dose but not low-dose enoxaparin substantially improves survival in cirrhotic patients with portal vein thrombosis Laura Turco Received Received
  FRI-219 Intrahepatic type II natural killer T cells switch to a pro-inflammatory cytokine profile in patients with autoimmune hepatitis Marcial Sebode Received Received
  THU-219 Sustained biochemical response to oral antibiotics in pediatric PSC and ASC are correlated to changes in gut microbiota during therapy Pauline Sambon Received Received
  THU-220 Primary biliary cholangitis specific T cell receptors on N-Ras high CD4 T cells Ryo Nakagawa Received Received
  SAT-220 Higher in-hospital and post-discharge mortality and hospital charges in cirrhotic patients with acute respiratory illness in the United States Pauline Nguyen Received Received
  FRI-220 Human chorionic-plate-derived mesenchymal stem cells restore hepatic lipid metabolism in a rat model of bile duct ligation. Yun Bin Lee Received Received
  THU-221 Validation of various prognostic models in primary biliary cholangitis in Korean patients Jeong-Ju Yoo Received Received
  FRI-221 In vitro rescue of ABCB11 nonsense mutations : induction of a readthrough of premature stop codons Rachida AMZAL Received Received
  THU-222 Imaging Features of Macroregenerative Nodules (MRN) in Primary Sclerosing Cholangitis: MR imaging characteristics. Andres Morgado Received Received
  SAT-222 Assessment of portal hypertension evolution in HCV cirrhosis patients with baseline large oesophageal varices after sustained virological response Antonio Olveira Martin Received Received
  FRI-222 The anti-inflammatory receptor TREM2 protects the liver from cholestatic injury in mice Ibone Labiano Received Received
  SAT-223 The impact of hepatic steatosis on portal hypertension Bernhard Scheiner Received Received
  THU-223 Effect of nalfurafine hydrochloride for refractory pruritus in patients with primary biliary cholangitis: a multicenter, post-marketing, single-arm, prospective study Minami Yagi Received Received
  SAT-224 Controlled attenuation parameter (CAP) does not predict hepatic decompensation in patients with advanced chronic liver disease Bernhard Scheiner Received Received
  FRI-224 Low-dose Interleukin-2 Expands the Number of Circulating Regulatory T cells in Patients with Treatment-Refractory Autoimmune Hepatitis Tiong Yeng Lim Received Received
  SAT-225 Thromboelastography guided blood product transfusion in cirrhosis patients with acute variceal bleeding: a Randomized Controlled Trial Gyanranjan Rout Received Received
  THU-226 Stratification of hepatocellular carcinoma risk using the GLOBE score in patients with primary biliary cholangitis - the Global PBC Study Group Willem J Lammers Received Received
  FRI-226 Deep immunophenotyping of liver infiltrating lymphocytes reveals distinct differences in the T cell compartment of patients with Primary Sclerosing Cholangitis Tobias Poch Received Received
  SAT-227 Non-selective beta-blockers increase liver mortality when MELD is =12 in a prospective 5 year follow-up cohort of alcoholic cirrhosis Paul Cales Received Received
  THU-227 A Dose-Response Relationship in the Association between Ursodeoxycholic Acid Treatment and Prolonged Transplant-free Survival in Primary Biliary Cholangitis Adriaan Van der Meer Received Received
  THU-228 Incidence of autoimmune hepatitis is increasing, while primary biliary cholangitis and primary sclerosing cholangitis have remain unchanged: a population-based study Mehul Lamba Received Received
  SAT-228 Men have higher mortality in cirrhosis: outcomes by gender and etiology in a large, diverse cohort Apurva Yeluru Received Received
  FRI-228 Necroptosis signalling pathway in hepatic fibrosis; role of receptor-interacting serine-threonine kinase 3 and mixed lineage kinase domain-like in cirrhosis Waqar Saeed Received Received
  FRI-229 Role of Toll-like receptor 4 (TLR4) in regulating severity of hyperammonemia and gene expression of urea cycle enzymes Annarein Kerbert Received Received
  THU-229 Autoantibody-negative autoimmune hepatitis presents more commonly with advanced fibrosis or cirrhosis Mehul Lamba Received Received
  SAT-229 Prior or On-treatment Infection Does Not AffectResponse to Treatment or Survival in Patients with Hepatorenal Syndrome Type 1(HRS-1) Florence Wong Received Received
  SAT-230 Anticoagulant treatment for atrial fibrillation and decompensation rate in patients with liver cirrhosis Irina Girleanu Received Received
  THU-230 Prognosis in patients with primary biliary cholangitis based on histological stage at diagnosis. A nationwide population-based study Lars Bossen Received Received
  FRI-230 Regulatory T cells modulate the concentration of short chain fatty acids and the Th function in response to induced bacterial traslocation episodes, and improve the integrity of the gut barrier in an experimental cirrhosis model. Oriol Juanola Received Received
  FRI-231 Characterization of the Protective Effects of Yaq-001on Organ Injury in Cirrhosis Francesco De Chiara Received Received
  SAT-231 Decreased Model for End-Stage Liver Disease (MELD) score after antiviral treatment predicts reduced risk of mortality and hepatic events in chronic hepatitis B related cirrhosis - a study of 1,729 subjects Lai-Hung, Grace Wong Received Received
  SAT-232 Propranolol Treatment Associated with Better Survival and Reduced Sepsis in Cirrhotic Patients with Hepatic Encephalopathy Pei-Chang Lee Received Received
  THU-232 Chloroquine in monotherapy is safe and effective for induction of remission in anti-SLA/LP positive patients with autoimmune hepatitis Débora Terrabuio Received Received
  FRI-232 Systemic inflammation and portal vein thrombosis in gastroesophageal varies xiaoquan HUANG Received Received
  THU-233 Health-Related Quality of Life in patients with autoimmune hepatitis Atsushi Takahashi Received Received
  SAT-233 Six-minute Walk Test and Sarcopenia in Predicting Mortality in Patients with Cirrhosis ThucNhi Dang Received Received
  SAT-234 The effect of primary prophylaxis therapy for large esophageal varices in patients with hepatocellular carcinoma Hsiao-Sheng Lu Received Received
  FRI-234 Simvastatin-loaded polymeric micelles are a new, safe and effective drug delivery system targeting liver sinusoidal endothelial cells Diana Hide Received Received
  FRI-235 Transcriptome analysis of human and murine cirrhotic livers identifies shared molecular pathways as potential targets to enhance cirrhosis regression Erica Lafoz Received Received
  SAT-236 Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in cirrhosis: a systematic review and meta-analysis of randomized controlled trials Roger F. Butterworth Received Received
  FRI-236 In cirrhotic rats, mitochondria-targeted antioxidant mitoquinone attenuates liver inflammation and fibrosis by modulating oxidative stress and mitophagy. Saadet Turkseven Received Received
  SAT-237 Deleterious effect of proton pump inhibitors on the disease course of cirrhosis Zsuzsanna Vitális Received Received
  THU-237 Independent Predictors of Primary Biliary Cholangitis (PBC) at High Risk for Progressive Course in the United States: Data from a Large- Real World Database Zobair Younossi Received Received
  FRI-237 Ascites NK cells are phenotypically distinct from blood and liver NK cells in patients with liver cirrhosis and become activated by bacterial stimulation in-vitro and during spontaneous bacterial peritonitis Philipp Lutz Received Received
  SAT-238 The impact of pulmonary arterial hypertension therapy in patients with portopulmonary hypertension: a single tertiary center cohort analysis Frederik Nevens Received Received
  FRI-239 Real world experience of lusutrombopag for thrombocytopenia in patients with liver cirrhosis Hitomi Takada Received Received
  FRI-240 Chronic liver damage causes a reduction in the number and a dysfunction of the activity of liver resident macrophages ELISA POSE Received Received
  SAT-241 Distinct MELD Trajectories in Liver Transplant Candidates with Hepatitis C and NASH Allison Kwong Received Received
  FRI-241 An Immuno-metabolic phenotype of Acute-on-Chronic Liver Failure predicts early mortality Rabiya Zia Received Received
  FRI-242 Etiology-specific hemostatic profiles in cirrhosis Sarah Bos Received Received
  FRI-243 Prediction of Blood Ammonia Levels in Modeled Human Liver Dysfunction and Application to Gut-Restricted Ammonia Lowering Therapeutics Christine Brew Received Received
  SAT-243 Effect of vardenafil on portal hemodynamics in patients with mild and moderate liver dysfunction: a randomized, placebo-controlled trial Rafael Paternostro Received Received
  SAT-244 Varices on CT is the surrogate of clinically significant portal hypertension and can predict survival in patients with cirrhosis Dong Ho Lee Received Received
  SAT-245 Predictors of Endoscopic High Risk EsophagealVarices in Compensated Cirrhosis: Can we Avoid Fibroscan? Julian Hercun Received Received
  THU-245 Class III (morbid) obesity is an independent risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis Vinay Sundaram Received Received
  FRI-246 Effectiveness of a practical nutritional intervention in advanced liver disease: a prospective study Dalila Costa Received Received
  THU-246 Regional variations in the development of acute-on-chronic liver failure (ACLF) in patients with cirrhosis and bacterial infections Florence Wong Received Received
  THU-247 Number of organ failures is a better predictor of waitlist mortality in those who die within 30 days of listing for liver transplantation Paul J. Thuluvath Received Received
  SAT-247 Second-look endoscopy and prolonged use of proton pump inhibitor and octreotide after variceal ligation reduce early bleeding rate in cirrhosis with large gastroesophageal varices: a single-blinded, single-centered and randomized controlled trial Anjiang Wang Received Received
  THU-248 Impact of receptor interacting protein kinase 3 levels on acute on chronic liver failure progression Takayuki Kondo Received Received
  FRI-248 The FXR agonist GS-9674 reduces fibrosis and portal hypertension in a rat model of NASH Philipp Schwabl Received Received
  SAT-248 Uncontrolled diabetes increases all causes of mortality and particularly cardiovascular death in patients with cirrhosis Fatima Higuera-de La Tijera Received Received
  THU-250 Combinations of inflammatory markers, soluble (s)CD163, mannose receptor (sMR) and neutrophil gelatinase associated lipocalin (NGAL), predicts mortality in patients with acute-on-chronic liver failure Henning Grønbæk Received Received
  FRI-250 LSECtin and CD206 participate in the regulation of the hepatic inflammatory response to E coli in a model of cirrhosis Esther Caparrós Received Received
  SAT-250 Increasing Burden of Hepatic Encephalopathy among Hospitalized Adults, With Significantly Higher Risk of In-Hospital Mortality in African Americans: An Analysis of the 2007-2013 Nationwide Inpatient Sample Grishma Hirode Received Received
  FRI-251 Changes of bile acids profile in different etiologies of liver cirrhosis and its association with neutrophil response Irina Komarova Received Received
  THU-252 Early management of critically ill cirrhotic patients admitted in ICU for gastrointestinal bleeding: wait day 3 to avoid taking a bad decision. Lucy Meunier Received Received
  SAT-253 Functional polymorphisms of innate immunity receptors are not risk factors for non-SBP type bacterial infections in cirrhosis Tamas Tornai Received Received
  THU-253 Dynamic assessment is superior to baseline assessment in prognostication of patients with acute on chronic liver failure Sahaj Rathi Received Received
  THU-254 Acute on Chronic Liver Failure-Comparison of patients identified by the European Association for the study of the Liver and the North American Consortium for study of End-Stage Liver Diseases Zita Galvin Received Received
  SAT-254 The prognosis following bacterascites is as poor as spontaneous bacterial peritonitis Ji Jade King Received Received
  FRI-254 Occult hepatitis B infection in hepatocellular carcinoma patients with negative HBsAg Danny Wong Received Received
  SAT-255 MELD-score underestimates mortality in patients with nosocomial spontaneous bacterial peritonitis Markus Kimmann Received Received
  THU-255 Liver transplantation in patients admitted to intensive care with acute-on-chronic liver failure Eleni Theocharidou Received Received
  FRI-255 Non-linear association between serum hepatitis B virus DNA levels and hepatocellular carcinoma risk in treatment-naive, non-cirrhotic chronic hepatitis B patients Gi-Ae Kim Received Received
  FRI-256 Hepatitis B Splice Variants are strongly associated with and are indeed predictive of hepatocellular carcinoma Peter revill Received Received
  SAT-258 Development and predictive validity of the Cirrhosis-associated Ascites Symptom Scale: A cohort study of 103 patients. Agnete Riedel Received Received
  FRI-258 Antiviral therapy can be avoided in most HBeAg-negative Caucasian patients in the Gray Zone Martin Bonacci Received Received
  SAT-259 Clinical, paraclinical and MR-spectroscopy profile in cirrhotic and non-cirrhotic portal hypertension patients with minimal hepatic encephalopathy Bertrand Hermann Received Received
  FRI-259 Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in chronic hepatitis D Antonella Olivero Received Received
  THU-259 Invasive fungal infections in Acute on chronic liver failure - An Asia Pacific experience from the AARC consortium Sunil Taneja Received Received
  SAT-260 Multimodal approach including MR-spectroscopy for the diagnosis of minimal hepatic encephalopathy Bertrand Hermann Received Received
  FRI-260 Soluble cytotoxic T-lymphocyte-associated antigen-4 (sCTLA-4) and soluble programmed cell death protein-1 (sPD-1) are predictive immune checkpoint seromarkers for spontaneous functional cure of chronic hepatitis B with opposite effects Hwai-I Yang Received Received
  THU-261 Hyperkalemia influences the outcome of patients with cirrhosis with acute decompensation (AD) and acute on chronic liver failure (ACLF) Andres Cardenas Received Received
  THU-262 Impact of organ failure in patients with acute on chronic liver failure (ACLF) and the newly defined AARC liver failure score in predicting 90 days survival-results from APASAL-ACLF research consortium (AARC) Apurva Pande Received Received
  SAT-262 Impact of an antimicrobial stewardship policy on the reduction of empirical antibiotic treatment failure and the spread of multidrug-resistant organisms in hospitalized cirrhotic patients simone incicco Received Received
  FRI-262 Identifying epigenetic markers for characterization of host response to hepatitis B virus infection during the development of hepatocellular carcinoma wan-jung wu Received Received
  SAT-263 Outpatient terlipressin infusion increases dietary intake and functional muscle strength in patients awaiting liver transplant Brooke Chapman Received Received
  FRI-263 External validation of clinical scoring system for the prediction of hepatocellular carcinoma in chronic hepatitis B treated by nucleotide/nucleoside analogue Masayuki KUROSAKI Received Received
  SAT-264 Dynamic Visual Processing in Patients with Decompensated Cirrhosis Katherine Wong Received Received
  FRI-264 Monitoring patients with a resolved hepatitis B virus infection for HBV reactivation Akihiro Tamori Received Received
  THU-265 Outcome of bacterial infections complicated or not by acute-on-chronic liver failure in patients with cirrhosis admitted to hospital for acutedecompensation. Michele Bartoletti Received Received
  SAT-265 The physical component of the SF-36 Quality of Life tool is an independent predictor of mortality in patients with severe ascites Daniel Zaldumbide Received Received
  FRI-265 Relationship between hepatitis B core-related antigen and chronic hepatitis B outcome in HBeAg negative patients: a 10-year longitudinal study Wai Pan To Received Received
  FRI-266 Real-world rates of hepatitis B surface antigen (HBsAg) seroclearance in patients with chronic hepatitis B (CHB): a systematic review, conventional aggregated data meta-analysis (ADMA) and individual patient data meta-analysis (IPDMA) Donghak Jeong Received Received
  SAT-266 Clinical frailty scale as a novel tool predicts unplanned hospitalisation and/or death in outpatients with cirrhosis. ANIRUDDHA PRATAP SINGH Received Received
  THU-266 Typing acute-on-chronic liver failure according to World Gastroenterology Organization working party definition in HBV-related patients Xiaoting Tang Received Received
  FRI-267 Association of common polymorphism in the Interleukin 1 beta gene with Hepatitis B virus-related hepatocellular carcinoma in Caucasians Janett Fischer Received Received
  THU-268 Relative adrenal insufficiency in acute-on chronic liver failure - a new futility marker? Anca Trifan Received Received
  SAT-268 Terlipressin for variceal bleeding induces severe plasma sodium disturbances in non-cirrhotic portal hypertension Peter Lykke Eriksen Received Received
  FRI-268 Effective hepatitis B vaccination by serologic results in the United States: a population-based study from 1999-2016 Michael Huan Le Received Received
  THU-269 The Combination of Acute-on-Chronic Liver Failure (ACLF) as defined by EASL-CLIF Consortium Definition and MELD Can Predict Post-transplant Survival in Patients with ACLF Uchenna Agbim Received Received
  SAT-269 Outcome after the use of SX-ELLA Danis bleeding stents for refractory variceal bleeding- a Vienna Multicenter Experience Nikolaus Pfisterer Received Received
  FRI-269 Suboptimal rates of effective hepatitis B vaccination in adults at high risk of infection in the United States from 1999-2014 Michael Huan Le Received Received
  SAT-270 The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites Nikolaus Pfisterer Received Received
  THU-270 Hemophagocytic Lymphohistiocytosis (HLH) in patients of Acute on chronic liver failure -Results of multination study from APASL-ACLF Research Consortium (AARC) Harsh Vardhan Tevethia Received Received
  FRI-270 Droplet digital PCR quantitation of HBV cccDNA pool and transcriptional activity in long-term nucleos(t)ide analogue treated patients Aurore Inchauspé Received Received
  THU-271 Human beta-defensin-1 is a highly predictive marker of mortality in patients with acute-on-chronic liver failure Ilianna Mani Received Received
  THU-272 Thromboelastography parameters in acute on chronic liver failure Sandeep Goyal Received Received
  SAT-272 Hemodynamic disturbances across different stages of decompensated cirrhosis and influencie on outcomes Marta García Guix Received Received
  FRI-272 Combination of HBV serological markers to predict the burden and productivity of intrahepatic HBV reservoir and disease progression in HBeAg negative Chronic Hepatitis B Romina Salpini Received Received
  SAT-273 Prevalence and clinic impact of rectal colonization by multidrug-resistant bacteria in descompensated cirrhosis Maria Hernandez-Tejero Received Received
  THU-273 Features of levels of neurospecific proteins in patients with hepatic encephalopathy Nataliia Dynnyk Received Received
  THU-274 Non inferiority of combination of slow continuous albumin,furosemide with low dose Terlipressin with Noradrenaaline infusion in ACLF patients in comparison to slow continuous albumin , furosemide and Terlipressin Gaurav Pandey Received Received
  SAT-274 Improving assessment of hepatic encephalopathy in outpatient clinics Floranne Hansa Received Received
  FRI-274 Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy Minjong Lee Received Received
  THU-275 Impact of response guided aggressive pharmacological therapy with slow continuous albumin, furosemide and terlipressin infusion in chronic liver failure consortium acute on chronic liver failure score Gaurav Pandey Received Received
  FRI-275 Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen level in the natural history of chronic HBV infection Gian Paolo Caviglia Received Received
  THU-276 Impact of Clostridium difficile 027 ribotype in decompensated cirrhotic patients Ainhoa Fernandez Received Received
  SAT-276 The time trend of hospital admissions, inpatient mortality rate, and hospital cost of hospitalizations associated with cirrhosis in the United States: an analysis on the National Inpatient Sample Donghak Jeong Received Received
  FRI-276 Pan-genotypic loop-mediated isothermal amplification assay (LAMP) for HBV: a simple, rapid and affordable point-of-care test to semi-quantify HBV DNA Yusuke Shimakawa Received Received
  SAT-277 Validation and modification of Baveno criteria to rule out high- risk varices in patients with compensated cirrhosis VARUN RAVINDRA TADKALKAR Received Received
  FRI-277 Basal core promoter mutations as potential predictors of an enlarged intrahepatic HBV reservoir and enhanced cccDNA transcriptional activity in HBeAg negative chronic hepatitis B infection Luna Colagrossi Received Received
  SAT-278 Outcomes of intrahepatic porto-systemic shunt in the treatment of portal vein thrombosis: a systematic review and meta-analysis Susana Rodrigues Received Received
  SAT-279 Clinically significant portal hypertension in chronic liver disease: always cirrhosis? Susana Rodrigues Received Received
  FRI-279 Early on-treatment alanine aminotransferase (ALT) normalization reduces risk of hepatic events in patients with chronic hepatitis B Lai-Hung, Grace Wong Received Received
  SAT-280 Screening of esophagogastric varices: performance of the "Expanded Baveno VI criteria" and the "platelet 150/MELD 6" strategy in all etiology compensated advanced chronic liver disease Giulia Tosetti Received Received
  FRI-280 Occult Hepatitis B infection is frequent and a risk factor of advanced liver disease in The Gambia, West Africa Gibril Ndow Received Received
  SAT-281 Combined elastin and collagen proportionate area (ECPA) sub-classifies cirrhosis and predicts clinical outcomes Avik Majumdar Received Received
  SAT-282 Transjugular Intrahepatic Portosystemic Shunt (TIPS) is highly effective in patients with a MELD score < 20 and does not require routine Doppler ultrasound follow-up Koos de Wit Received Received
  THU-282 Behavioral and clinical factors and Direct Acting Antiviral effectiveness in HCV/HIV co-infection; clinical experience from the TRIO network. Gregory Huhn Received Received
  FRI-282 Long-term outcomes and significance of HBeAg Seroclearance in Chronic Hepatitis B: Novel Predictive Scores for HCC and HBsAg seroclearance Yan Yue James Fung Received Received
  SAT-283 Efficacy of Liver Stiffness Measurement and Platelet Count in Screening for High Grade Varies in Patients with Cirrhosis. Ashish Agarwal Received Received
  FRI-283 Serum WFA+-M2BP level as a diagnostic marker of HBV-related HCC: A case-control study Natthaya Chuaypen Received Received
  THU-283 HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy. Vincenza Calvaruso Received Received
  THU-284 Therapy with DAAs in patients with chronic hepatitis C and advanced chronic kidney disease: Real-world experience from the German Hepatitis C-Registry (DHC-R) Johannes Wiegand Received Received
  FRI-284 The incidence of hepatocellular carcinoma in hepatitis B virus infected persons of different origins, living in Sweden Ann-Sofi Duberg Received Received
  THU-285 Uniform addition of ribavirin to sofosbuvir/velpatasvir for genotype 3 patients with cirrhosis: real world outcomes Alison Boyle Received Received
  SAT-286 Cardiac fibrosis and coronary atherosclerosis in cirrhosis. Indications of cirrhotic cardiomyopathy? Signe Wiese Received Received
  SAT-287 The role of bile acids in the development of structural myocardial changes and cardiac dysfunction in patients with cirrhosis Signe Wiese Received Received
  THU-287 treatment of chronic hepatitis C with direct acting antivirals and its effect on body mass index and hepatic steatosis as measured by controlled attenuation parameter Hend Shousha Received Received
  FRI-287 Quantification of hepatitis B virus covalently closed circular DNA by a peptide nucleic acid-clamping PCR method Chau-Ting Yeh Received Received
  FRI-288 Long-term outcome of hepatitis delta compared to HBV monoinfection Anika Wranke Received Received
  SAT-288 Hepatopulmonary syndrome: a spontaneously reversible condition? Variability in prevalence in a prospective follow-up study of cirrhotic patients Aurelia Chiricuta Received Received
  THU-288 factors associated with nonresponse in a cohort of 10655 chronic hepatitis C patients treated with direct acting antivirals Hend Shousha Received Received
  SAT-289 Is obesity an additional negative factor in sarcopenic cirrhotic patients? Daria D´ambrosio Received Received
  THU-289 Incidence and outcome of portal vein thrombosis in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3-year study Elisabetta Degasperi Received Received
  FRI-289 The WHO guidelines for chronic hepatitis B fails to detect half of the patients in need of treatment Hanna Aberra Received Received
  SAT-290 Liver cirrhosis and wound healing: Activation of von Willebrand factor and platelets Lasse Langholm Received Received
  FRI-290 A new utility of HBcrAg - a pan-genotypic predictor of mother to child HBV transmission Ivana Carey Received Received
  SAT-291 The incidence of ulcer bleeding post endoscopic band ligation of esophageal varices Salvador Machlab Received Received
  FRI-291 Virological heterogenity of hepatitis delta among Vietnamese populations Thanh Binh Mai Received Received
  THU-292 Sustained virologic response (SVR) to direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC): a systematic review and meta-analysis Fanpu Ji Received Received
  SAT-292 Association between hospital type and transplant-free survival in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunts (TIPS): A population-based study. Jeffrey Mah Received Received
  FRI-293 Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection Arianna Battisti Received Received
  THU-293 Management of patients with chronic kidney disease in the setting of interferon-free treatment for chronic HCV hepatitis ELENA LAURA ILIESCU Received Received
  SAT-293 A simple patient-reported instrument can predict development of overt hepatic encephalopathy Mette Munk Lauridsen Received Received
  THU-294 Untreated HCV in HIV/HCV co-infection; data from the TRIO network. Dushyantha Jayaweera Received Received
  FRI-294 Patients with genotype 5 hepatitis delta infection have a favourable outcome of disease and better treatment response to pegylated interferon therapy compared to genotype 1 patients Michelle Spaan Received Received
  SAT-294 The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention Mette Munk Lauridsen Received Received
  SAT-295 Transjugular Intrahepatic Portosystemic Shunt Versus Beta-blocker and/or Endotherapy for Prevention of Variceal Rebleeding in adults with EHPVO Guohong Han Received Received
  THU-295 Changing landscape of HCV treatment in Germany: Data from a large real-world cohort 2014-2017 Jörg Petersen Received Received
  THU-296 Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis Fred Poordad Received Received
  FRI-296 Clinical Features of HDV Infection in Mongolian Patients Anir Enkhbat Received Received
  THU-297 Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy Velia Chiara Di Maio Received Received
  SAT-297 A prospective evaluation of symptom burden,opioid risk in cirrhosis patients Mina Niazi Received Received
  FRI-297 Monitoring of subjects with previous Hepatitis B exposure on Rituximab for Hepatitis B reactivation and on demand treatment for Hepatitis B reactivation is safe and reduces cost Victoria Ekstrom Received Received
  THU-298 Impact of direct acting antiviral treatment in hospital admission rates in patiens with cirrhosis and hepatitis C virus (HCV) infection. Álvaro Hidalgo Romero Received Received
  SAT-298 Critical flicker frequency improves its diagnostic and predictive accuracy of hepatic encephalopathy by decreasing the dispersion between measures. Javier Ampuero Received Received
  THU-299 A national study of risk for non-liver cancer in people with hepatitis C treated with direct acting antivirals or an interferon-based regimen Charlotte Lybeck Received Received
  SAT-299 Four years outcomes of Baveno VI low risk cirrhotic patients Priscila Pollo-Flores Received Received
  SAT-300 A novel sonographic parameter for the quantification of muscle mass in cirrhosis Kazufumi Kobayashi Received Received
  FRI-300 Disease progression is affected by pattern of serum alanine aminotransferase (ALT) dynamics in a cohort of patients with hepatitis B e antigen (HBeAg)-negative chronic infection: 4 years follow-up of a prospective longitudinal study (ALBATROS Study) Viola Knop Received Received
  SAT-301 Repeated episodes of acute kidney injury (AKI) on the transplant waiting list: Impact on post-liver transplantation renal and patient outcomes Shuetfong Neong Received Received
  FRI-301 Serum Mac-2-binding protein glycosylation isomer in assessing liver fibrosis in chronic hepatitis B infection lung-yi mak Received Received
  THU-302 Outcomes of direct-acting antiviral therapy for chronic hepatitis C following unrestricted access in Australia: Real-world outcomes from the state of South Australia James Haridy Received Received
  FRI-302 Changes in serum levels of the novel mac-2 binding protein glycosylation isomer (M2BPGi) and risk of hepatocellular carcinoma (HCC) among chronic hepatitis B (CHB) patients treated with nucleos(t)ide analogues (NAs) Yao-Chun Hsu Received Received
  FRI-303 A risk score combining quantitative hepatitis B surface antigen and core-related antigen levels to predict off-therapy relapse after cessation of nucleos(t)ide analogues in patients with chronic hepatitis B Yao-Chun Hsu Received Received
  THU-303 Risk and outcome of hepatitis B virus (HBV) reactivation during chronic hepatitis C treatment with direct-acting antivirals (DAAs) in patients with HCV-related advanced fibrosis: a single-center experience Roberta D´Ambrosio Received Received
  SAT-303 Gender differences regarding sarcopenia development in chronic liver disease Atsushi Hiraoka Received Received
  THU-304 Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study Chen-Hua Liu Received Received
  SAT-304 Assessment of subclinical hepatic encephalopathy by using EncephalApp Stroop test and brain MRI Ioan-Cristian Lupescu Received Received
  FRI-304 Acute hepatitis B in adulthood: not such a benign disease. Mar Riveiro-Barciela Received Received
  FRI-305 The first results of genotyping of virus hepatitis D and virus hepatitis B in Kazakhstan Bibigul Ilyassova Received Received
  THU-305 "How do you feel about your diagnosis of Hepatitis C today?" The emotional benefits of direct-acting antiviral therapy. Sarah Montague Received Received
  SAT-305 Impact of antibiotic prophylaxis of spontaneous bacterial peritonitis on colonization and infections with multidrug-resistant bacteria Marcus Mücke Received Received
  THU-306 Rapid virological response, as a predictor of sustained virological response of Sofosbuvir and Ribavirin in Korean patients with genotype 2 chronic hepatitis C virus infection Hyun Young Woo Received Received
  FRI-306 The levels of cytokines in progression of chronic hepatitis D Bibigul Ilyassova Received Received
  SAT-306 The Indication, Dosage and Duration of Proton Pump Inhibitors in Liver Cirrhosis Marianne De Roza Received Received
  FRI-307 Assessment of Hospitalizations and Comorbidities in 2138 Hepatitis B Patients Followed in Diverse Specialist Care Clinics Based on Administrative Data Analysis. The Canadian Hepatitis B Network. Carla Coffin Received Received
  SAT-307 the effect of new infection control measures for the prevention of hospital acquired infections in cirrhotic patients Vincenza Di Gregorio Received Received
  THU-307 Ledipasvir 90mg/sofosbuvir 400mg for treatment of children with CHC genotype 4: Single Centre experience. Gamal Sheha Received Received
  FRI-308 Can pre-core region mutations distinguish between HBeAg negative genotype A1 and A2 patients with similar HBV DNA viral load levels? Natalie Bolton Received Received
  SAT-308 Presepsin, C reactive protein and procalcitonin have similar accuracy for bacterial infection and sepsis in decompensated cirrhosis Fischer Petra Received Received
  THU-308 Safety and effectiveness of DAA treatment and clinical outcomes of HCV liver transplanted patients with recurrent hepatitis C infection: a single center 3-year study from Italy Federica Invernizzi Received Received
  THU-309 Efficacy and safety of IFN-free DAA therapy in HIV/HCV co-infected patients: Results from a pan-European study Lars Peters Received Received
  FRI-309 switching immunoglobulin base therapy to nucleoside/nucleotide analogoes monothearpy is safe&effective as preventive therapy of reccurent HBV in liver transplanted patients- single centre experience orly sneh Received Received
  SAT-309 Predictive factors of esophageal varices recurrence after prophylactic endoscopic band ligation Jaime Rodrigues Received Received
  SAT-310 A study evaluating outcomes of cirrhotic patients managed in a dedicated liver cirrhosis clinic and factors influencing survival. David Kockerling Received Received
  SAT-311 Frialty is an independent predictive factor of hospital admissions and falls in patients with cirrhosis Eva Roman Received Received
  THU-312 Identification of novel resistance associated substitutions for sofosbuvir in HCV genotype 3a David Smith Received Received
  SAT-312 Cardiac assessment in children with chronic liver disease: cholestatic and non-cholestatic Tawhida Yassin Abdel Ghaffar Received Received
  THU-313 Utilization and outcomes of elbasvir/grazoprevir in genotype 1B Chronic Hepatitis C: updated retrospective data analyses from the Trio network. Naoky Tsai Received Received
  SAT-313 Non-invasive predictors of varices in non-cirrhotic portal hypertension Morven Cunningham Received Received
  FRI-313 Validation of AASLD Treatment Guideline Eligibility Based on Disease Outcomes of Large Community and Clinical Cohorts of Chronic Hepatitis B (CHB) Patients Dong Hyun Lee Received Received
  SAT-314 Impact of adrenal dysfunction on psoas muscle thickness assessed by computed tomography in patients with liver cirrhosis Graziella Privitera Received Received
  FRI-314 Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B Yun Bin Lee Received Received
  THU-315 Efficacy, safety and clinical outcomes of Paritaprevir/Ombitasvir/r + Dasabuvir 8 weeks (3D8): results from a spanish real world cohort (Hepa-C) Marc Puigvehí Received Received
  FRI-315 Quantitative Hepatitis B surface antigen in different phases of Vietnamese chronic HBV infected patients Huong Nguyen Received Received
  SAT-316 Endoscopic radiofrequency ablation for the treatment of gastric antral vascular ectasia in cirrhotic patients: a bi-centric clinical and economical cost-effective analysis Marco Senzolo Received Received
  THU-316 Multidisciplinary Support Program for patients with addictions and suspected chronic hepatitis C (MSP ADIC-C) to improve their evaluation and access to antiviral treatment Marc Puigvehí Received Received
  FRI-316 HBeAg Negative Chronic Hepatitis B Patients with HBV-DNA Levels Between 2000-20000 IU/ml and Normal Aminotransferases are Really Inactive? Bilal Ergül Received Received
  FRI-317 Which pregnancy biomarkers predict post-delivery ALT flares in mothers with chronic hepatitis B? Salome Imbert Received Received
  THU-318 Direct acting antiviral treatment improves hepatitis C-related neurocognitive impaiment Joaquin Cabezas Gonzalez Received Received
  FRI-318 Adherence to AASLD Treatment Guidelines on Treatment Initiation Among Treatment-Eligible Patients with Chronic Hepatitis B: Experiences from Primary Care and Referral Practices Vy Hoang Nguyen Received Received
  FRI-319 Durability of HBsAg loss during or after antiviral Treatment in a predominantly middle european collective Gerlinde Teuber Received Received
  THU-319 Effectiveness of 8 vs. 12 week ledipasvir-sofosbuvir (LDV/SOF) in black, treatment naïve patients with non-cirrhotic, genotype 1 HCV and baseline viral load Michael Curry Received Received
  SAT-320 Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity Hiroaki Takaya Received Received
  FRI-320 The effect of PEG-IFN add on or switch to on HBsAg clearance in HBeAg- CHB patients recieving entecavir treatment Lei Yan Received Received
  THU-320 Effectiveness of elbasvir/grazoprevir in patients with cirrhotic genotype 1 or 4 Chronic Hepatitis C: updated retrospective data analyses from the Trio network. Michael Curry Received Received
  FRI-321 A virological response to PEG-IFNa treatment of hepatitis delta is associated with an improved clinical long-term outcome: 10 years follow-up of the HIDIT-1 study Anika Wranke Received Received
  FRI-322 Novel markers predict HBs-antigen seroclearance in chronic hepatitis B patients from the SWAP clinical trial Wah Wah Phyo Received Received
  THU-322 High efficacy of IFN-free DAA therapy for acute HCV infection in HIV patients David Chromy Received Received
  FRI-323 Pharmacokinetics and pharmacodynamics modeling of ritonavir boosted lonafarnib therapy in HDV patients: A phase 2 LOWR HDV-3 study Harel Dahari Received Received
  FRI-324 Modeling serum HBsAg, HBV DNA and transaminase kinetics during REP 2139 monotherapy in chronic HBeAg+ HBV infection Harel Dahari Received Received
  SAT-325 High Mortality Rate in HBV-related Cirrhosis Patients with HEV Superinfection Tai-Chung Tseng Received Received
  FRI-326 Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV / HDV co-infection: 18 month follow-up results from the REP 301-LTF study. Andrew Vaillant Received Received
  THU-326 HCV treatment responses among people who use drugs (PWUD): an evaluation of patients on and off opiate agonist therapy (OAT) in a real-life setting Julie Holeksa Received Received
  SAT-326 Clinical features and outcomes of hepatitis E in patients with underlying chronic liver disease: a respective case-control study Yijin Wang Received Received
  SAT-327 Risk factors of hepatitis E related liver failure: a restrospective case-control study Yijin Wang Received Received
  THU-327 VIEKIRA PAK (ritonavir-boosted paritavir/ombitasvir and dasabuvir) associated drug-induced interstitial lung disease: Case series with systematic review YU JUN WONG Received Received
  THU-328 HCV Genetic Diversity by Geographic Region within Genotype 1-6 Subtypes among Patients Treated with Glecaprevir and Pibrentasvir Gretja Schnell Received Received
  SAT-328 The role of hepatitis E in acute non-traumatic neuropathy in China: a prospective case-control study Yijin Wang Received Received
  FRI-328 Every-two-week ropegienterferon alfa-2b is safe with higher hepatitis B e antigen seroconversion rate in interferon naive patients with chronic hepatitis B infection: A phase 2, open label, randomized, active control, dose finding study Yi-Wen Huang Received Received
  FRI-329 HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B Mina Farag Received Received
  SAT-329 Clinical impact, morbidity and mortality of Hepatitis E at tertiary referral centres in central Europe Johannes Hartl Received Received
  THU-329 Is treatment of hepatitis C with controlled generic direct acting antiviral drugs effective? An Egyptian experience Mahmoud Elzalabany Received Received
  SAT-330 Dynamics of HBsAg clearance in a UK cohort of chronic HBV infection Philippa Matthews Received Received
  FRI-330 Determination of the optimum timing of the start of nucleoside analogue by FIB-4 index for hepatitis B patients from the viewpoint of suppressing hepatocarcinogenesis Shuhei Hige Received Received
  THU-330 Real-life experience of ritonavir-boosted paritaprevir, ombitasvir plus ribavirin for treatment of HCV-GT4 in Egyptian patients with severe renal impairment Heba Omar Received Received
  FRI-331 Treatment of chronic hepatitis B and renal impairment in patients with and without cirrhosis Vinh Vu Received Received
  SAT-331 Blood products as source of HEV transmission? 1-year experience with routine HEV screening at a tertiary center Thomas Horvatits Received Received
  THU-331 The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is similar in patients who failed interferon-based treatment with first generation protease inhibitors Ewa Janczewska Received Received
  THU-332 Characteristicsand retreatment of HCV DAA failure patients: Real-life experience Isaac Ruiz Received Received
  SAT-332 Poor outcome of acute hepatitis E in liver cirrhosis and transplant recipients Mar Riveiro Barciela Received Received
  FRI-332 Is renal impairment associated with chronic hepatitis B - a propensity score matched study of healthy non-hepatitis B patients compared to patients with untreated chronic hepatitis B Vinh Vu Received Received
  FRI-333 Comparison of fibrosis-adjusted long-term clinical outcomes in patients with minimally active chronic hepatitis B who did not undergo antiviral therapy vs. those with complete virological response by antiviral therapy Hye Won LEE Received Received
  SAT-333 Preceding Hepatitis E Virus Infection in Patients with Myasthenia Gravis Lin Wang Received Received
  SAT-334 Hepatitis A affecting men having sex with men: ongoing outbreak in Israel, December 2016- September 2017 Orna Mor Received Received
  SAT-335 Incidence of hepatitis E infection in renal transplant patients in The Netherlands Robin Erken Received Received
  THU-335 A comparison of elbasvir/grazoprevir, ledispasvir/sofosbuvir and velpatisvir/sofosbuvir therapy among people who use drugs (PWUD): real world experience Arshia Alimohammadi Received Received
  FRI-335 Loss of HbsAg is enough to discontinue long-term therapy with Nucleos(T)ide analogues in HbeAg negative CHB patients in real clinical practice? Andreas Kapatais Received Received
  THU-337 Safety and effectiveness comparing generic and original sofosbuvir-based treatment regimens in patients with hepatitis C: A prospective multicenter study from Argentina Ezequiel Ridruejo Received Received
  THU-338 Integrated efficacy and safety of glecaprevir/pibrentasvir in patients with psychiatric disorders David BACK Received Received
  FRI-339 Clinical and virological predictors of response after antiviral therapy interruption in HBeAg-negative chronic hepatitits B Sabela Lens Received Received
  THU-339 Real world effectiveness of Ledipasvir/Sofosbuvir based regimens in hepatitis C virus genotype 1,2 and 3 infection within national hepatitis C elimination program in the country of Georgia Tengiz Tsertsvadze Received Received
  SAT-339 Longitudinal analysis of HCV full genomes in patients failing NS5A inhibitors reveals the selection of novel amino acid substitutions outside NS5A Slim Fourati Received Received
  THU-340 Effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection: real-world data from Georgian hepatitis C elimination program Tengiz Tsertsvadze Received Received
  FRI-341 Association of metabolic adipokines with persistence of fibrosis in chronic hepatitis B during long-term nucleoside analogue therapy Ka-Shing Cheung Received Received
  FRI-342 Tenofovir Disoproxil Fumarate use during Pregnancy and Infant Bone Health and Growth: the Tenofovir in Pregnancy (TiP) Study Athena Kourtis Received Received
  SAT-343 DEAD-box helicases DDX5 and DDX17 areinvolved in the fine tuning of hepatitis B virus minichromosome transcriptional regulation Fleur CHAPUS Received Received
  FRI-343 Updated follow-up analysis in the REP 401 protocol: treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a Andrew Vaillant Received Received
  SAT-344 Rolling circle amplification and nanopore-based deep sequencing of full-length HBV genomes Philippa Matthews Received Received
  THU-344 Impact of CD4+ T-cell count on sustained virologic response to direct-acting antivirals in HIV-negative cancer patients with chronic hepatitis C Haley Pritchard Received Received
  FRI-344 A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 240 Jing-Hang Xu Received Received
  THU-345 The real-world safety and efficacy of sofosbuvir plus ribavirin for eldery patients over 75 years of age Hideyuki Tamai Received Received
  SAT-345 LTPprodrug technology offers new generation nucleotide antiviral agents Lin Zhi Received Received
  FRI-345 Sustained virological suppression and improved renal function with reduced dose tenofovir disoproxil fumarate in renally compromised patients with chronic hepatitis B Seng Liem Received Received
  FRI-346 Low serum HBsAg and HBV DNA predict response of peg-interferon addition to entecavir in HBeAg positive chronic hepatitis B Seng Liem Received Received
  SAT-346 Conservation and variation of the hepatitis E virus open reading frame 2 proteome Shaoshi Zhang Received Received
  THU-346 Sustained virologic response rates (SVR-12) for chronic hepatitis C genotype 6 patients treated with Ledipasvir/Sofosbuvir or Sofosbuvir/Velpatasvir Sam Trinh Received Received
  THU-347 Clinical and virological characteristics of DAA-experienced patients with chronic HCV infection treated with sofosbuvir/velpatasvir/voxilaprevir: results from the Frankfurt Resistance Database Johannes Vermehren Received Received
  SAT-347 Mutations in HCV NS3 but no Sec14L2 variants alter HCV RNA replication of natural occuring viruses in cell culture Sandra Ciesek Received Received
  FRI-347 Renal outcomes in chronic hepatitis b patients treated with tenofovir disoproxil fumarate or entecavir: a propensity score matched study Sam Trinh Received Received
  FRI-348 Peginterferon is superior to nucleos(t)ide analogues for reduction ofchronic hepatitis B-related hepatocellular carcinoma in patients with high-riskscore Peipei Ren Received Received
  THU-348 Are patients treated with direct antiviral agents for HCV infection at greater risk for extrahepatic malignancies? Tarek Saadi Received Received
  SAT-348 Expanding the donor pool- decontamination of HCV RNA positive kidneys with methylene blue Sandra Ciesek Received Received
  THU-349 Real world adherence to Direct-Acting Antivirals in a cohort of drug users in Rome, Italy. Elisabetta Teti Received Received
  SAT-349 Seeking genetic determinants of resistance to hepatitis C virus infection in a highly resistant cohort Daniel Felmlee Received Received
  FRI-349 Validation of the EASL 2017 HBV clinical practice guidelines criteria for switching patients long-term treated with Tenofovir difumarate to Entecavir or Tenofovir alafenamide in a real life setting Alessandro Loglio Received Received
  FRI-350 The long-term risk and outcome of non-neoplastic portal vein thrombosis developing in compesated caucasian HBV cirrhotics treated with Tenofovir or Entecavir Alessandro Loglio Received Received
  SAT-350 A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro Lorenzo Piermatteo Received Received
  SAT-351 Palmitoylation Determines the Subcellular Localization of the Hepatitis E Virus ORF3 Protein Jérôme Gouttenoire Received Received
  FRI-351 Clinical and genetic predictors of HCC occuring in caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years Alessandro Loglio Received Received
  THU-351 Adverse reactions of Direct-acting AntiviralAgents (DAAs) in HCV patients: our experience Diana Padovani Received Received
  FRI-352 Pharmacokinetic-Pharmacodynamic Modeling of Tenofovir Exalidex in HBV Subjects Robert Foster Received Received
  THU-352 A Comparison of renal function before and after treatment in chronic hepatitis C patients who achieved sustained viral response with direct acting antivirals Paul Fitzmorris Received Received
  THU-353 Fast-track HCV check-up enhances possibility of sustained virologicalresponse in HCV infected patients Teresa Antonini Received Received
  THU-354 Grazoprevir/elbasvir dosing according to viral load and NS5A resistance: real world confirmation of the efficacy of EASL guidance Fiona Marra Received Received
  SAT-354 Compare HBsAg retention in the endoplasmic reticulum (ER) and the ER stress between the cells transfected or infected by the wild type and pre-S HBV mutants using in vitro transfection and in vivo infection of FRG mice Jenny Yuh-Jin Liang Received Received
  FRI-354 HeberNasvac: Novel Therapeutic Vaccine Against Chronic Hepatitis B Gerardo Guillen Received Received
  THU-355 Impact of HCV viral load on elbasvir/grazoprevir effectiveness in Chronic Hepatitis C: updated retrospective data analyses from the Trio network. Steven Flamm Received Received
  FRI-355 At least 90% long-term adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir Young-Suk Lim Received Received
  SAT-355 HBV Peptide Array Demonstrates Candidate Mechanisms of CRV431 Anti-HBV Activity Robert Foster Received Received
  SAT-356 Assessing the in vitro anti-HBV activity of combinations including CRV431, TXL, and prototype capsid assembly modulators Robert Foster Received Received
  THU-356 Therapeutic Drug Monitoring of DAAs overcomes contra-indications against anti-epileptics in HCV treatment (HepNed003) minou van seyen Received Received
  FRI-357 Serum hepatitis B virus DNA and pregenomic RNA levels and kinetics in nucleos(t)ide analogue treated and untreated subjects Emily Butler Received Received
  SAT-357 Establishment of a method to compare antiviral effect of drug products by human hepatitis B virus infected humanized chimeric mice Hatsune Enomoto Received Received
  THU-357 What impact do the new direct acting antiviral drugs have on the patients quality of life? Marta Gentili Received Received
  THU-358 Significant changes of HCV patient characteristics over time in the era of direct antiviral agent (DAA) therapy - are all HCV subpopulations treated similarly? - Results from the GErman hepatitis C COhort (GECCO) Stefan Christensen Received Received
  FRI-359 Hepatitis B surface antigen reduction by switching from long-term preceding nucleoside/nucleotide analog administration to pegylated interferon or tenofovir Tamaki Nobuharu Received Received
  THU-359 National Quality Control and Validation of Hepatitis C NS3, NS5A and NS5B Genotypic Resistance Testing Valeria Cento Received Received
  FRI-361 Virological response and safety in a cohort of immigrant patients affected by chronic hepatitis delta treated with PEG-IFN Lucio Boglione Received Received
  SAT-361 HBV reactivation and changes in interferon-stimulated gene expression during treatment of direct-acting antivirals for HCV: Analyses in a novel in vitro model for HBV-HCV coinfection using human induced pluripotent stem cell–derived hepatic cells Yasuhiro Asahina Received Received
  FRI-362 RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV Man-Fung Yuen Received Received
  THU-363 Efficacy and safety of glecaprevir/pibrentasvir in renally-impaired patients with chronic hepatitis C virus genotype 1-6 infection Marcello Persico Received Received
  SAT-363 Statin inhibits HDV assembly, secretion, and large hepatitis delta antigen-Smad3-Twist mediated epithelial-mesenchymal transition Jaw-Ching Wu Received Received
  FRI-363 Comparison of event-free survival between DAA and IFN-based antiviral therapy for HCV, adjusted for disease severity Lisette Krassenburg Received Received
  FRI-364 The number needed to treat to prevent one clinical event at 2 years after antiviral treatment for HCV with DAAs compared to IFN-based therapy Lisette Krassenburg Received Received
  SAT-364 Murine hepatocytes with humanized sodium taurocholat polypeptide (NTCP) limit HDV infection in vivo independent of adaptive immune responses Marc Luetgehmann Received Received
  THU-364 Multicenter study on outcome of HCV elimination using LDV/SOF combination in Mongolians Lkhaasuren Nemekhbaatar Received Received
  FRI-365 TLL1 variants do not predict the development of de-novo hepatocellular carcinoma in HCV cirrhotics treated with IFN-free DAA-based regimens Pietro LAMPERTICO Received Received
  SAT-365 Antiviral properties and liver specific delivery of a TLR1/2 ligand in HBV-infected in vitro and in vivo models Julie Lucifora Received Received
  SAT-366 Inhibition of Hepatitis Virus X protein (HBx) in HBV-Infected Primary Human Hepatocytes leads to the Reappearance of the Smc5/6 Complex Rudolf Beran Received Received
  THU-366 Sofosbuvir/Ledipasvir : Efficacy and tolerance in HCV positive patients naïve or pre-treated in Cameroun serge tchamgoue Received Received
  SAT-367 FXR is a proviral factor whose binding to HBV genome is modulated by FXR agonist and correlates with presence of the activated chromatin mark H3K4me3 in an HBx dependant manner Benoît Lacombe Received Received
  THU-367 Hepatitis B virus reactivation during direct-acting antiviral therapy in hepatitis B/C co-infected patients on hemodialysis Chunhua Hu Received Received
  THU-368 High efficacy of resistance guided retreatment of Genotype 3 in real life Federico Garcia Garcia Received Received
  FRI-368 Long-term immunological and clinical impact of HCV eradication with direct acting antivirals (DAAs) in patients with HCV-associated cryoglobulinemia vasculitis Martin Bonacci Received Received
  FRI-369 Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: a sinlge-center prospective 3 year study Roberta D´Ambrosio Received Received
  SAT-369 Reduction of serum infectivity of Hepatitis Delta virus-infected patients treated with Myrcludex B: An in vitro assay to determine infectious units Katrin Schöneweis Received Received
  FRI-370 The Impact of HCV Eradication by IFN-free Regimens on the Transition of Precancerous Hepatic Nodules to HCC: a Prospective Observational Study Hidenori Toyoda Received Received
  SAT-370 The protein complex structural maintenance of chromosomes reappears after interferon alpha treatment in hepatitis B virus infected humanized mice but its presence does not hinder viral rebound Maura Dandri Received Received
  FRI-371 Impact of curative HCC history on the Development of HCC after the Eradication of HCV by DAA Therapy in Patients with HCV Infection Hidenori Toyoda Received Received
  SAT-371 Hepatitis B virus escapes non-canonical CTL effector function Dirk Wohlleber Received Received
  THU-371 Real world experience with twelve weeks of therapy without ribavirin in genotype 1 HCV infected compensated cirrhotics Dorota Zarebska-Michaluk Received Received
  FRI-372 Impact of Direct-acting Antiviral Agents (DAAs) on Liver Function in Patients with Chronic Hepatitis C Virus (HCV) Infection Hidenori Toyoda Received Received
  THU-372 Sofosbuvir-based treatment of viral hepatitis C genotype 3 infection - a Polish real-world study. Dorota Zarebska-Michaluk Received Received
  SAT-372 HBsAg transcomplementation of defective HBV genomes in HBeAg negative chronic HBV infected patients Kai-Henrik Peiffer Received Received
  FRI-373 Sustainable Improvement of Patient-Reported Outcomes (PROs) in Cirrhotic Patients with Hepatitis C (HCV) who Achieved Sustained Virologic Response (SVR) Zobair Younossi Received Received
  SAT-373 Recapitulation of the complete HDV replication cycle in a novel hepatoma cell line allows for efficient antiviral compound evaluation Florian Lempp Received Received
  THU-373 Naturally occurring drug resitance substitutions in the NS5A and NS5B regions in Hepatitis C virus genotype 2 and response to sofosbuvir plus ribavirin therapy Kazuhiko Hayashi Received Received
  FRI-374 The Impact of Sustained Virologic Response on Severe Fatigue in Patients with Chronic Hepatitis C: The Role of HCV Viremia and Co-Morbidities Zobair Younossi Received Received
  SAT-374 Proteomic analysis of hepatitis B virus cccDNA-specific associated proteins identifies crucial regulators of viral transcription and RNA processing Barbara Testoni Received Received
  THU-374 Effectiveness and safety of direct-acting antiviral therapies in chronic hepatitis C infections patients with cirrhosis in Turkey Fehmi Tabak Received Received
  SAT-375 Biogenesis and Function of Intracellular Hepatitis B e Antigen Bidisha Mitra Received Received
  FRI-376 Resolution of clinically significant portal hypertension after sustained virologic response to interferon-free regimens prevents hepatic decompensation Mattias Mandorfer Received Received
  FRI-377 Long-term changes of liver elasticity in HVC-infected patients with SVR after treatment with direct-acting antivirals Veronika Pietsch Received Received
  THU-377 Real-life efficacy and safety of daclatasvir and asunaprevir therapy for genotype 1b chronic hepatitis C patients without NS5A resistance-associated substitution: A nationwide study in South Korea Sook-Hyang Jeong Received Received
  SAT-377 Hepatitis E virus activates signal transducer and activator of transcription 3 to facilitate virus replication Wenshi Wang Received Received
  SAT-378 Pro-fibrogenic mediator Osteopontin is intimately involved in Chronic Hepatitis B and promotes cccDNA production Sandra Phillips Received Received
  FRI-378 Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma in SVR achieved hepatitis C patients with interferon-free treatment Yutaka Yasui Received Received
  THU-378 Genotype 3 Infection in HIV/HCV co-infected subjects in the DAA era: real life data from the ICONA/HepaICONA Foundation cohorts. Roberto Rossotti Received Received
  THU-379 Safety and Efficacy of Daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: data from the ICONA/HepaICONA Foundation cohorts. Roberto Rossotti Received Received
  SAT-380 Control of glycokinase activity by the HCV protein NS5A increases lipogenesis Olivier DIAZ Received Received
  THU-380 Cost-effectiveness analysis of baseline testing for resistance-associated polymorphisms to optimise treatment duration in genotype 1 non-cirrhotic treatment-naive patients with chronic hepatitis C virus Christopher Fawsitt Received Received
  SAT-381 Evolution and persistence of resistance-associated substitutions of hepatitis c virus after daclatasvir plus asunaprevir treatment failures Yechan JEONG Received Received
  FRI-381 Sustained and Continued Improvement in Hepatic Fibrosis Beyond the First Year Following Hepatitis C Virus Treatment Robert Wong Received Received
  SAT-382 FXR agonist GW4064 represses HBV replication in adult but not in young C3H/HeN mice after HBV transduction with rAAV2/8-HBV Patrice ANDRE Received Received
  FRI-382 The role of Hepatitis C virus eradication with DAA on insulin resistence regulation Ilaria Bortoluzzi Received Received
  THU-382 Resistance analysis of hepatitis C virus NS5A gene in Brazilian patients infected with genotypes 1 and 3 treated with Daclatasvir Elisabeth Lampe Received Received
  FRI-383 Therapy with Oral Directly Acting Agents in Hepatitis C Infection is Associated with Reduction in Fibrosis and Increase in Hepatic steatosis. . Shalimar Received Received
  THU-383 Variables associated with persistence of elevated ALT after SVR in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry (DHC-R) Stefan Mauss Received Received
  SAT-383 Cellular RetinoicAcid-Binding Proteins Regulation of Hepatitis C Virus Infection Takeshi Saito Received Received
  THU-384 Time to Viral Suppression Does Not Impact SVR in Patients Treated with Glecaprevir/Pibrentasvir for 8 Weeks Christoph SARRAZIN Received Received
  THU-385 Identification, by Cold-PCR, of treatment-resistant HCV mutations in baseline samples of patients treated with DAAs. Antonio Madejón Received Received
  SAT-385 Sodium taurocholate cotransporting popypeptide (NTCP) variants modulate HDV entry according to their function as a bile acid transporter but do not influence the antiviral effect of Myrcludex-B Olympia Anastasiou Received Received
  FRI-385 In hepatitis C patients with cirrhosis who achieve SVR with treatment, reduction in transient elastography measures does not translate to reduced risk of hepatocellular carcinoma: A prospective cohort study. Jessica Howell Received Received
  FRI-386 Risk of de novo hepatocellular carcinoma after DAA treatment within two years following treatment with Ombitasvir/Paritaprevir/ritonavir±Dasabuvir±Ribavirin in the AMBER– real world experience study Robert Flisiak Received Received
  THU-386 Persistence and risk of transmission of the hepatitis C virus NS5B S282T substitution in a HIV-positive man who has sex with men Astrid Newsum Received Received
  SAT-386 Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein Laurence COCQUEREL Received Received
  THU-387 On treatment HCV-RNA evaluation in real-life: still a role in the era of direct acting antiviral agents? Francesca Ceccherini Silberstein Received Received
  FRI-387 Antiviral therapy can prevent in HCV infected patients relapse of diffuse large B cell lymphoma Adriano Pellicelli Received Received
  FRI-388 Prospective follow up of 80 patients with addictive behaviors and advanced fibrosis after treatment of chronic HCV infection with DAA : a suboptimal management camille barrault Received Received
  FRI-389 Predictors of clinical improvement among HCV patients with advanced liver disease treated with DAA: a single center experience. Chiara Mazzarelli Received Received
  THU-389 Ethnic Differences in HCV-related HCC (HCV-HCC) Outcomes: Report from the Real-World Evidence by the Asia Pacific Rim Liver Consortium for HCC (REAL-HCC) Debi Prasad Received Received
  SAT-389 Understanding the multiphasic viral kinetics of cute HBV infection observed in humanized uPA/SCID mice using an agent-based modeling approach Harel Dahari Received Received
  SAT-390 Understanding HDV and HBV dynamics during acute co-infection in humanized uPA/SCID chimeric mice using an agent-based modeling appraoch Harel Dahari Received Received
  FRI-390 Sustained virologic response leading to improved long-term metabolic outcomes Benjamin Emmanuel Received Received
  THU-390 Changes in the characteristics of hospital admissions due to complications of cirrhosis in the era of direct-acting antivirals (DAAs) against HCV Miguel Fraile Received Received
  FRI-391 High virological cure rate and low rate of reinfection in a project to eradicate HCV in people who inject drugs at risk for non-adherence to direct-acting antivirals in Vienna Michael Gschwantler Received Received
  THU-391 Validation of a clinical scoring system to predict risk of hepatocellular carcinoma (HCC) in an ethnically diverse cohort of patients with chronic hepatitis C virus (HCV) infection Mike Tzuhen Wei Received Received
  SAT-391 Molecular diversity of HDV strains that spread in France: a study of 2224 clinical strains prospectively collected during fifteen years Athenaïs Gerber Received Received
  FRI-392 Circulating microparticles and thrombotic risk in patients with HCV-related cirrhosis who underwent DAA treatment Alberto Zanetto Received Received
  THU-392 Minimal Monitoring Of Direct-Acting Antiviral Therapy Within A Real World, Urban Population Sarah Kattakuzhy Received Received
  SAT-392 Molecular diversity of HBV and HDV amino-acid sequences involved in HDV virion morphogenesis according to HBV and HDV genotypes: study of 1590 clinical strains Athenaïs Gerber Received Received
  FRI-393 A cost-effectiveness analysis of shortened direct-acting antiviral treatment for mild chronic hepatitis C virus Christopher Fawsitt Received Received
  SAT-394 Prevalence, Pathogenesis and Cross-species Transmission of A Novel Hepatitis E Virus from Bactrian Camels Lin Wang Received Received
  SAT-395 Mitochondrial Electron Transport Chain Complex III: a promising antiviral target for hepatitis E virus Changbo Qu Received Received
  THU-396 A universal offer of blood borne virus testing substantially increases diagnosis and treatment of hepatitis C in prisons Stuart Mcpherson Received Received
  FRI-396 Treatment of HCV infection with DAAs is associatedwith lower HCC recurrence and improved survival after liver transplant Katharina Willuweit Received Received
  SAT-396 HCV induced-miR-21 activation triggers lipid accumulation and promotes viral replication Sophie Clément-Leboube Received Received
  SAT-397 Hepatitis E virus replication and interferonresponse in human placental-derived cells Patrick BEHRENDT Received Received
  FRI-397 Effect of hepatitis C sustained virological response on the endothelial dysfunction and the cardiovascular risk. HepCAR study. Rocio Munoz hernandez Received Received
  THU-397 Multifactor risk evaluation in patients who have eradicated HCV infection: an interim analysis in the PITER cohort Loreta Kondili Received Received
  FRI-398 The impact of Direct Antiviral Agent Therapy on liver fibrosis in patient with Advanced fibrosis related chronic hepatitis C Blaise Kutala Received Received
  SAT-398 Are there different profiles in microRNA expression in HBV/HDV co-infected patients reflecting plasma HBsAg and HBcrAg concentrations? Ivana Carey Received Received
  THU-398 DNA methylation and immune cell markers demonstrate associations of accelerated aging with chronic HCV/HIV co-infection and liver fibrosis Shyamasundaran Kottilil Received Received
  FRI-399 Effects of direct-acting antiviral treatment of chronic hepatitis C on macrophage activation, liver stiffness, metabolic liver function and portal hypertension in cirrhosis patients Tea Lund Laursen Received Received
  SAT-399 Dimerization: A structural feature for the protection of Hepatitis E virus capsid protein against trypsinization Wenjuan Wei Received Received
  SAT-400 The correlations between HBV markers in sera and HBVcccDNA for genotypes matsui takeshi Received Received
  FRI-400 Involvement of angiotensin II/angiotensin-(1-7) fibrinolytic pathway in improvement of liver fibrosis in chronic hepatitis C patients who had sustained virological response by direct-acting antiviral therapy: a prospective trial Nicha Teeratorn Received Received
  FRI-401 The lack of improvement in liver stiffness after SVR in HCV compensated advanced chronic liver disease is associated with the risk of presenting liver related events Monica Pons Delgado Received Received
  THU-402 Changes in Serum Neurotransmitters (NTs) are Associated with Changes in Patient Reported Outcomes (PROs) and Neurocognitive Performance (NP) in patients with Hepatitis C Virus (HCV)-Genotype 1 (GT1) who achieved Sustained Virologic Response (SVR) Zobair Younossi Received Received
  FRI-402 Health utilities in Spanish chronic hepatitis C patients treated with direct acting antivirals in real life conditions Regina Juanbeltz Received Received
  THU-403 Patient-Reported Outcomes in Chronic Hepatitis C: The Impact of Placebo, Active Treatment, and Sustained Viral Eradication Zobair Younossi Received Received
  FRI-404 Controlled Attenuation Parameter (CAP) values of Fibroscan® compatible with steatosis in patients with chronic hepatitis C and changes after sustained virological response Teresa Broquetas Received Received
  THU-404 Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia Marianne Martinello Received Received
  FRI-405 Recurrent viremia after successful hepatitis C virus (HCV) therapy with direct-acting antivirals in a cohort of people who use drugs (PWUD) Arshia Alimohammadi Received Received
  THU-405 The Rapid-EC study - a feasibility study of point-of-care testing in community clinics targeted to people who inject drugs in Melbourne, Australia. Bridget Williams Received Received
  SAT-406 Depletion of RIPK1 in hepatocytes exacerbates PolyI:C and Murine Hepatitis Virus induced liver damage Michel SAMSON Received Received
  FRI-406 Changes in liver steatosis and lipid metabolism accompanied by successful interferon-free DAAs therapy in HCV infected patients; a comprehensive analysis Naoki Kawagishi Received Received
  FRI-407 Impact of direct acting antiviral drugs on HCV- related decompensated liver cirrhosis El-Sayed Tharwa Received Received
  THU-407 Evaluation of APRI index to identify cirrhosis prior to direct-acting antiviral HCV treatment Joseph Doyle Received Received
  SAT-407 A novel chimpanzee adenoviral vectored HBV vaccine, encoding multiple HBV antigens with a shark invariant chain adjuvant, for use in HBV immunotherapy Senthil Kumar Chinnakannan Received Received
  THU-408 Hepatitis C treatment success in primary and tertiary care among people with HCV/HIV coinfection Joseph Doyle Received Received
  THU-409 REtrieval And Cure of Hepatitis C patients in the Utrecht province in the Netherlands: REACH Patricia Kracht Received Received
  SAT-409 Induction of specific CD4+ T cell helper responses following recombinant ChAd3/MVA vaccination against HCV Ilaria Esposito Received Received
  FRI-409 Direct Acting Anti-viral treatment for hepatitis C results in a rapid reduction in MRI measures of hepatic microstructure Robert Scott Received Received
  THU-410 Preliminary analysis of the Prime Study; a randomized controlled trial comparing the hepatitis C care cascade in primary care vs. tertiary care Amanda Wade Received Received
  SAT-410 Induction of liver sinusoidal endothelial cells immune activation by HBeAg during HBV infection Jia Liu Received Received
  FRI-410 Clinical consequences of occult HCV infection in a post-liver transplant population Jeffrey Kahn Received Received
  THU-411 Strategic Elimination: Efficacy of Hepatitis C treatment in People Who Inject Drugs (PWID) in an urban, underserved clinic in the United States Christian Ramers Received Received
  SAT-411 Regulation of antiviral CD8 T cell response by MMP mediated soluble CD100 releasing in HBV infection Jia Liu Received Received
  FRI-411 Incidence of de-novo hepatocellular carcinoma after treatment with direct antiviral agents for hepatitis C: a multicenter prospective cohort study from Latin America. Federico Piñero Received Received
  FRI-412 Impact of sustained virological response in the use of concomitant drugs in hepatitis C virus infected patients with comorbidities Elena González-Colominas Received Received
  THU-412 Among 1945-1965 Birth Cohort Patients with At Least One Additional Hepatitis C Virus (HCV) Risk Factor, One in Eight Were Positive for HCV Antibody: An Underserved Safety-Net Population Experience Grishma Hirode Received Received
  FRI-413 Noninvasive diagnosis of fibrosis in the patients with hepatitis C virus infection treated with direct-acting antivirals Hiroshi Numao Received Received
  THU-413 Among patients being treated in addiction center, alcohol consumption increases the risk of hepatitis C seroconversion and the severity of hepatic fibrosis in those seropositive for hepatitis C virus. Michel Doffoël Received Received
  THU-414 Prevalence and clinical characteristics of portal vein thrombosis in HCV related cirrhosis: a cohort of Egyptian patients Omar Elshaarawy Received Received
  SAT-414 Hepatitis B virus entry in primary human hepatocytes initiates toll-like receptor 2-dependent immune signaling. Ruth Broering Received Received
  FRI-414 Impact of SVR to IFN-free DAA therapy on steatosis in HIV/HCV coinfected patients David Chromy Received Received
  SAT-415 Probing new HBV therapies using fine needle aspirates to sample compartmentalised liver-resident immunity and hepatocytes Upkar S. Gill Received Received
  THU-415 Outcomes of an opt-out strategy for Hepatitis C testing in the East Midlands prison estate Kathryn Jack Received Received
  FRI-415 Sustained virological response predicts fibrosis regression in chronic hepatitis C patients treated with direct acting antivirals-a single tertiary care centre experience RAJENDRA GUNJAL Received Received
  SAT-416 HBV-specific T cell responses in low replicating inactive carrier patients are independent of Hepatitis B surface antigen load Upkar S. Gill Received Received
  FRI-416 Long-term evolution of thrombocytopenia in patients with chronic hepatitis C and advanced fibrosis after sustained virological response with direct antiviral agents. Judith Gómez- Camarero Received Received
  FRI-417 Treatment of Patients with Decompensated Cirrhosis with DAAs Improves Clinical Symptoms without Affecting their MELD Score. John Romano Received Received
  SAT-417 Outcome of anti-viral immunity in the liver is shaped by the level of antigen expressed in infected hepatocytes Katrin Manske Received Received
  THU-417 Antiviraltreatment of Hepatitis C improve glucosemetabolism along the entire spectrum from normal glucose tolerance to diabetes. Sara Bianco Received Received
  FRI-418 Development of hepatocellular carcinoma following HCV eradication by direct-acting antivirals: Real-life experience from Japanese multicenter cohort Eiichi Ogawa Received Received
  SAT-418 The RNA genome of hepatitis E virus robustly triggers antiviral interferon response Wenshi Wang Received Received
  SAT-419 The impact of HBsAg on general and HBV-specific immunity Nina Le Bert Received Received
  THU-420 Early HCV Viral Kinetics in the Setting of Transplantation of Kidneys from HCV-infected Deceased Donors into HCV-negative Recipients David Goldberg Received Received
  SAT-420 Normalization of NK cell phenotype is delayed after successful interferon-free therapy in cirrhotic patients with chronic HCV infection. Elena Perpiñan Received Received
  SAT-421 Transcriptome profiling of hepatitis B virus-infected human hepatocyte derived from chimeric mice with humanized liver Shingo Nakamoto Received Received
  THU-421 Screening for neurocognitive dysfunction in non-cirrhotic chronic hepatitis C infection in an Irish academic unit. Damien Ferguson Received Received
  FRI-421 Prevalence and stratification of NAFLD/NASH in a UK and US cohort using non-invasive multiparametric MRI Stephen Harrison Received Received
  THU-422 Decrease in blood borne viral infections, liver fibrosis and drug use in a Danish prison population Peer Brehm Christensen Received Received
  THU-423 Strong correlation of hepatitis B virus prevalence among Mongolian adults 40 to 65 years old of age with HCC mortality rate: A result from the national general hepatitis screening program Uurtsaikh Baatarsuren Received Received
  FRI-423 Non-invasive liver tests in electronic health records of patients with non-alcoholic fatty liver disease: combined analysis from four European countries William Alazawi Received Received
  THU-424 Identification of the fast progression and spontaneous regression liver fibrosis phenotypes by a serological collagen turnover profile Sara Toftegaard Hjuler Received Received
  SAT-424 Upregulated innate immune responses in a hepatitis C virus exposed uninfected cohort Kris Bennett Received Received
  FRI-424 Algorithm to identify patients with an activity grade > 2 in type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD)- development in a large prospective multicenter UK study - Philip Newsome Received Received
  THU-425 Field evaluation of Xpert (Cepheid) Hepatitis C Virus assay for RNA quantification in Genotype 6 predominant patient population in Cambodia Sokchea Yann Received Received
  FRI-425 Noninvasive mapping of fibrosis and inflammation in nonalcoholic fatty liver disease: isolating fibrogenesis in the Space of Disse with MRI R2 multicomponent relaxometry Hilton Leao Filho Received Received
  THU-426 Screening for hepatitis C at the emergency department: babyboomers should also be screened in Belgium. Rob Bielen Received Received
  SAT-426 HLA-A2 restricted CD8+ T cell immune hierarchy towards full length Hepatitis E virus (HEV) for T cell-based therapy in chronic HEV. Chaifen Soon Received Received
  FRI-427 An algorythm for screening for liver fibrosis in primary care using population-based data Isabel Graupera Received Received
  SAT-427 Development and characterization of unique Hepatitis C virus neutralizing antibodies associated with infection outcome Shiri Elmedvi Baran Received Received
  THU-427 Factors related to differential HCV therapy success or failure based on clinic location within a single health system: A possible role for increasing access to co-located support services? Jacqueline Sherbuk Received Received
  FRI-428 Comparison of ElastPQ Shear-wave Elastography (ElastPQ-SWE) and FibroScan Transient Elastography (F-TE) for liver fibrosis staging in patients with NAFLD. Davide Roccarina Received Received
  SAT-428 EP2 associated with the inflammatory storm in HBV related acute-on-chronic liver failure Yunyun Wang Received Received
  THU-429 Strong increase of acute HCV infections in HIV-negative men having sex with men laurent Cotte Received Received
  FRI-429 Establishing reliability criteria forLiver ElastPQ Shear-wave Elastography (ElastPQ-SWE): comparison between 3, 5and 10 measurements. Davide Roccarina Received Received
  SAT-429 Cytokine-Dependent Activation of MAIT Cells by the TLR8 agonist GS-9688 but not the TLR7 Agonist GS-9620 Hassan Javanbakht Received Received
  SAT-430 Characterization of theHEV-specific CD8+ T-cell response in acute and chronic Hepatitis E virus infection Janine Kemming Received Received
  THU-430 Implementation of a Unique Hepatitis C Care Continuum Model in a Resource Limited Setting Poonam Mathur Received Received
  FRI-430 Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study Louise Alferink Received Received
  THU-431 The IL6 -174 C/C genotype is associated with high quality of life scores in patients with chronic hepatitis C Luciana Diniz Silva Received Received
  SAT-431 A pan-genotype HCV T cell vaccine, in a simian adenovirus vector, to target T cell epitopes conserved across multiple HCV genotypes Timothy Donnison Received Received
  SAT-432 Performance of recomWell HEV and Wantai HEV in acute Hepatitis E and German blood donors Friedhelm Struck Received Received
  SAT-433 Ex vivo characterization of co-inhibitory molecules on MHC class II tetramer positive HCV-specific CD4+ T cells in HCV infection Christin Ackermann Received Received
  THU-433 Cost-effectiveness of one-time screening for hepatitis C virus infection in Korean general population Kyung-ah kim Received Received
  FRI-433 Electronic-nose breath print distinguishes non-alcoholic fatty liver disease from healthy lean control: a pilot study Rohit Sinha Received Received
  THU-434 Case finding can successfully re-engage persons lost to follow-up and increase treatment rates in hepatitis C virus services lynsey corless Received Received
  SAT-434 Association of PD1 and TIM3 Polymorphisms with HBV Susceptibility Chunhong Huang Received Received
  FRI-434 A study of breath metabolome in Non-alcoholic fatty liver disease Rohit Sinha Received Received
  THU-435 Direct acting anti-viral therapy rescues neutrophil dysfunction in hepatitis C infection by reduction of heamolysis Bettina Leber Received Received
  FRI-435 Appropriateness of inclusion criteria according to transaminases ALT in studies assessing performances of non-invasive tests in type-2 diabetes patients (T2D) Thierry Poynard Received Received
  THU-436 Treatment of Adolescents genotype 4 chronic HCV infected patients with Ledipasvir/Sofosbuvir Combination: a real world experience Dina Attia Received Received
  SAT-436 A systematic comparison reveals dynamic differences in early adaptive immune responses of acute-resolving versus chronic HBV replication Qin Wang Received Received
  FRI-436 Performance and reliability of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity Andreas Drolz Received Received
  FRI-437 Controlled attenuation parameter is useful in the diagnosis of fatty liver disease and allows to identify patients with high vascular risk as well as those with advanced liver disease Marta González Received Received
  THU-437 Impact of a hepatitis C virus electronic medical record screening alert for baby boomers Robyn Teply Received Received
  FRI-438 Effects of bariatric surgery on Non-alcoholic fatty liver disease: The role of macrophage-mediated the systemic inflammation Noemí Cabré Received Received
  FRI-439 Magnetic Resonance Elastography versus Transient Elastography in detection of fibrosis in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participant date Cynthia Hsu Received Received
  SAT-441 Alcoholic Liver Disease replaces HCV Infection as the Leading Indication for Liver Transplantation in the United States Daniel Zaldumbide Received Received
  FRI-441 Utility and limitation of non-invasivefibrosismarkersfor predicting the prognosis in biopsy-proven Japanese NAFLD patients Takanori Ito Received Received
  THU-441 Stk25 Antisense Oligonucleotide Treatment Reverses Glucose Intolerance, Insulin Resistance, and NAFLD in Mice Margit Mahlapuu Received Received
  THU-442 Decreased circulating peripheral blood Mucosal Associated Invariant T (MAIT) cells is correlated with insulin resistance in patients with Nonalcoholic fatty liver disease (NAFLD) Johnny Amer Received Received
  FRI-442 FibroScan stiffness and CAP in the evaluation of cardiovascular risk assessment in patients with NAFLD Rosa Lombardi Received Received
  SAT-442 Individualized prediction of the risk of liver-related death in patients with alcoholic cirrhosis Marot Astrid Received Received
  FRI-443 Repeatability and Reproducibility of Multiparametric Magnetic Resonance Imaging of the Liver Henry Wilman Received Received
  SAT-443 Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis Marot Astrid Received Received
  THU-443 Angiopoietin-2 as therapeutic target for pathological angiogenesis and inflammation in non-alcoholic steatohepatitis Sander Lefere Received Received
  THU-444 Lipid-induced ASK1 activation in hepatocytes and Kupffer cells mediates the increased vulnerability of fatty liver to Ischemia/Reperfusion injury in mice Chiara Imarisio Received Received
  FRI-444 The Community based management of NAFLD Study (COMMANDS): Improved diagnosis and referral using a novel integrated care pathway lynsey corless Received Received
  SAT-445 Prevalence of alcoholic steatosis in the general adult Portuguese population Jorge Antonio M.Carvalho Pratas Leitao Received Received
  FRI-445 Enhanced liver fibrosis (ELF) score accurately detects advanced fibrosis in nonalcoholic fatty liver disease (NAFLD). Rudolf E. Stauber Received Received
  THU-445 Role of rare pathogenic mutations in the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease serena pelusi Received Received
  SAT-446 Making sense of Liver Function tests: Is the Intelligent Liver Function Test (iLFT) cost-effective? Kathleen Boyd Received Received
  FRI-446 Genetic variations of three important anti-oxidative enzymes: SOD2, CAT and CPX1 in non-alcoholic steatohepatitis Yi-Shin Huang Received Received
  FRI-447 Comparison of conventional ultrasound signs to current state-of-the-art MRI method for detection of hepatic steatosis Mi Mi Kim Received Received
  THU-447 Metabolomic patterns associated with known genetic variants for hepatic steatosis and non-alcoholic steatohepatitisidentify biomarkers that may be of utility in predicting adverse liver outcomes Jake Mann Received Received
  SAT-448 Higher Early Post-Liver Transplant Mortality in Recipients with Severe Alcoholic Hepatitis Versus Alcoholic Cirrhosis Brian Lee Received Received
  THU-448 Gut barrier dysfunction contributes to the pathological progression of nonalcoholic fatty liver disease induced by high fat diet in mice Jinghua Peng Received Received
  THU-449 Inhibitionof IL-1 signaling in hepatocytes retains insulin sensitivity and protects fromhepatocellular injury in non-alcoholic fatty liver disease (NAFLD). Nadine Gehrke Received Received
  FRI-449 A non-invasive biomarker of hepatic inflammation based on magnetic resonance imaging Tim St Pierre Received Received
  SAT-449 Bayesian sparse regression modelling more accurately predicts mortality risk than commonly used prognostic scoring systems in patients with severe alcoholic hepatitis Stephen Atkinson Received Received
  FRI-450 Temporal assessment of the non-invasive fibrosis scores FIB-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS) in a retrospective cohort study among patients with Non-Alcoholic Fatty Liver Disease (NAFLD) Carolina Muñoz Codoceo Received Received
  THU-450 Mechanism for Hypertriglyceridemia and Effect of Fibrate Coadministration During Acetyl-CoA Carboxylase Inhibitor Treatment Leigh Goedeke Received Received
  SAT-450 Insufficient diagnostic accuracy of general practitioners and routine liver function tests lead to high risk of under-referrals of patients with alcohol induced advanced liver fibrosis Thor Lars Hansen Received Received
  SAT-451 Delineating Complement Activation Molecular Patterns in Patients with Alcoholic Hepatitis Rebecca McCullough Received Received
  FRI-451 In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease Amalia Gastaldelli Received Received
  THU-451 Effect of exercise on gut microbiota and metabolic status modulation in an in vivo model of early obesity and NAFLD Sara Carbajo-Pescador Received Received
  FRI-452 Excess weight has a major impact on hepatic fibrosis by users of psychoactive substance Michel Doffoël Received Received
  THU-452 The paracrine effect of visceraladipose tissue obtained at bariatric surgery on primary human hepatic stellatecells grown in human 3D healthy liver scaffolds Krista Rombouts Received Received
  SAT-452 Presence of IgA isotype F-actin is frequent in patients with cirrhosis and consitutes the risk of progressive disease course Boglárka Balogh Received Received
  THU-453 Integrative analysis of NGS data highlight a genetic variant in ATG7 gene as a novel risk factor for nonalcoholic fatty liver disease progression. Guido Alessandro Baselli Received Received
  SAT-453 The TIM3-Gal9 immune checkpoint axis is inter-linked with severity of Alcoholic Liver Disease. Antonio Riva Received Received
  FRI-453 Hepatic microRNA and phosphoproteomic analysis provide insights about hepatic collagen deposition and stage of fibrosis in non-alcoholic steatohepatitis Zobair Younossi Received Received
  SAT-454 Interleukin-22 binding protein in alcoholic hepatitis Sidsel Støy Received Received
  THU-454 Effect of Combined Farnesoid X Receptor Agonist (INT747) and Dipeptidyl Peptidase-4 Inhibitor (sitagliptin) on Liver Fibrosis. Naotaka Shimozato Received Received
  THU-455 Efficacy of statins for the treatment of non-alcoholic steatohepatitis (NASH) with mild portal hypertension Miren Bravo Received Received
  FRI-455 Liver and pancreatic steatosis in children are both assosiated with metabolic syndrome but have different influence on insulin sensitivity and glucose metabolism Olha Lukianenko Received Received
  SAT-456 Collagen proportionate área is an independent predictor of long term outcome in patients with alcoholic liver disease Marta Guerrero Misas Received Received
  SAT-457 Hepatoprotective Biomarkers, Amphiregulin and Soluble Fas, IncreaseDuring ELAD Treatment in Alcoholic Hepatitis Subjects Jason Lapetoda Received Received
  THU-457 Nicotine enhances lipid accumulation and lipotoxicity in hepatocytes via suppression of autophagy. Shunhei Yamashina Received Received
  FRI-457 Metabolomics in the progression of fatty liver disease Jacopo Troisi Received Received
  FRI-458 Comparison of HepaFat-Scan and controlled attenuation parameter for the estimation of hepatic steatosis in patients with non-alcoholic fatty liver disease using histology as the reference standard Wah-Kheong Chan Received Received
  THU-458 Involvement of the CREB-E2F2-PPAR axis in non-alcoholic fatty liver disease development and progression to hepatocarcinoma Patricia Aspichueta Received Received
  SAT-458 The use of proton pump inhibitors among patients with alcoholic cirrhosis is not related with increased risk of death Ulrich Bang Received Received
  SAT-459 miRNA regulation of macrophage M1/M2 polarization of Kupffer cells and PBMCs in alcoholic liver disease Adam Kim Received Received
  FRI-459 Measuring what matters to patients: the development of the NASH-CHECK, a new patient-reported outcome instrument for nonalcoholic steatohepatitis Maria Magdalena Balp Received Received
  THU-459 Akkermansia spp. mediates protection from obesity-associated NAFLD development in germ free mice following intestinal microbiota transplantation from high fat diet and quercetin treated donors David Porras Received Received
  THU-460 Bile acid composition modulate insulin resistance in non-diabetic patients with NAFLD Chiara Rosso Received Received
  FRI-460 Spatial systems lipidomics reveals nonalcoholic fatty liver disease heterogeneity. Klara Scupakova Received Received
  SAT-460 The correlation of obesity with morbidity and mortality in alcoholic hepatitis. yasir yasiralazzawi Received Received
  SAT-461 Serum metabolic profiling for the identification of patients with severe alcoholic hepatitis adelina horhat Received Received
  FRI-462 FIBROSpect®NASH Serum Test Identifies Advanced Liver Fibrosis in Patients with NonalcoholicSteatohepatitis: Results of a Validation Study Rohit Loomba Received Received
  THU-462 Non-alcoholic steatohepatitis impairs Kupffercell-mediated immune tolerance in the mouse liver Stéphanie Lacotte Received Received
  SAT-463 Corticosteroid treatment is associated with a resolution of altered CD4+ T cell phenotype in patients with severe alcoholic hepatitis Ashwin Dhanda Received Received
  FRI-464 ELF test in NAFLD: poorconcordance with liver stiffness values Laura Iogna Prat Received Received
  THU-464 The vanin 1-cysteamine pathway regulates immune tolerance upon lipid-induced oxidative stress in non-alcoholic fatty liver disease Olivier Govaere Received Received
  SAT-465 Masked hemolysis as novel factor contributing to hepatic iron overload in ALD Vanessa Rausch Received Received
  THU-465 BAFF neutralization ameliorates the evolution of experimental NASH Salvatore Sutti Received Received
  FRI-465 Aetiology and severity of liver disease in HIV positive patients with suspected NAFLD: lessons from a cohort with available liver biopsies Laura Iogna Prat Received Received
  THU-466 The multifactorial pathogenesis of nonalcoholic fatty liver disease: connecting inflammation and oxidation Fedra Luciano-Mateo Received Received
  SAT-466 Use of rifaximin in alcoholic hepatitis: Pilot study. Cesar Jimenez Received Received
  THU-467 Expression of the chemokine CCL24 and its receptor in the sera and livers of patients with non-alcoholic fatty liver disease Yaakov Maor Received Received
  FRI-467 A new score to predict presence of advanced fibrosis in NAFLD and comparison with established scoring systems Hannes Hagström Received Received
  FRI-468 Evaluation of Severity of Hepatic Fibrosis and Steatosis in Biopsy-proven NAFLD Patients Using MR Imaging, Transient Elastography, and Serum Biomarker Young-Sun Lee Received Received
  THU-468 LJN452 (tropifexor) attenuates steatohepatitis, inflammation, and fibrosis in dietary mouse models of nonalcoholic steatohepatitis Bryan Laffitte Received Received
  THU-469 EDP-305 modulates lipoprotein metabolism via distinct chromatin and microRNA regulatory mechanisms Lijuan Jiang Received Received
  FRI-469 Monocyte subpopulations for non-invasive diagnosis of NAFLD and NASH in a bariatric patient collective Katharina Staufer Received Received
  SAT-471 Maternal dietary patterns and the risk of large-for-gestational age births Satomi Minato Received Received
  THU-471 Inhibition of IL6 trans-signaling leads to NAFLD, mature-onset obesity and metabolic syndrome tali lanton Received Received
  THU-472 Genetic and functional analysis of FGF21 in NAFLD/NASH Rocío Gallego-Durán Received Received
  SAT-472 Impact of short term weight loss (very low calorie diet vs bariatric surgery) on hepatic insulin resistance and plasma lipidomic profile Chiara Barbieri Received Received
  FRI-472 Positive predictive value of a physician diagnosis of non-alcoholic steatohepatitis is low and risks high rates of unnecessary liver biopsy Anna Roskilly Received Received
  FRI-473 Screening for liver fibrosis using transient elastography by fibroscan and fibrotest in type 2 diabetic patient Julia Sandler Received Received
  THU-473 Divergent effects of RIP3 and MLKL inhibition on HF diet induced steatosis Waqar Saeed Received Received
  FRI-474 Body mass index influences Controlled Attenuation Parameter (CAP) values measured with Fibroscan® M probe. When should we evaluate steatosis with the XL probe? Teresa Broquetas Received Received
  THU-474 Micro RNA 199a-3p attenuates hepatic lipogenesis through regulating specific protein 1. Yang Cheng Received Received
  THU-475 RIPK1 depletion exacerbates progression of liver fibrosis in high fat diet induced non-alcoholic steatohepatitis (NASH) in mice Jacques Le Seyec Received Received
  SAT-475 Prediction of decompensation events in NASH cirrhosis patients Roberta Forlano Received Received
  SAT-476 A mobile application for the management and follow-up of patients with Non-Alcoholic Fatty Liver Disease Roberta Forlano Received Received
  FRI-476 Feasibility and utility of controlled attenuation parameter and transient elastography in the assessment of nonalcoholic fatty liver disease severity in children Andrea Scott Received Received
  FRI-477 Optimal cutoff value of assessing changes in intrahepatic fat amount by using the controlled attenuation parameter in a longitudinal setting Bo-Kyeong Kang Received Received
  SAT-477 Lipofuscin is detected in early stages of the disease in liver biopsies of patients with Non-Alcoholic Fatty Liver Disease Roberta Forlano Received Received
  THU-477 Clinical-grade human liver mesenchymal stem cells reduce NAS score and fibrosis progression in advanced stage NASH pre-clinical model through immunomodulation Maria Mercedes Binda Received Received
  THU-478 Ablation of Interleukin-4 Receptor alpha in macrophages ameliorated steatohepatitis and fibrosis in murine model of non alcoholic steatohepatitis (NASH) Muhammad Ashfaq-Khan Received Received
  FRI-478 Saroglitazar Treatment Prevents NASH, Eliminates Hepatocyte Ballooning, and Significantly Improves Serum LFTs, Lipids and and Insulin Resistance in DIAMOND(tm) Mice Compared to Pioglitazone Benchmark Daniel Zaldumbide Received Received
  FRI-480 Fibrosis stage improvement in nonalcoholic steatohepatitis: a systematic review of placebo treated participants in randomized controlled trials Anna Roskilly Received Received
  THU-480 Evaluation of the rodent Octodon degus as a pre-clinical model of liver fibrosis Sarah Brockbank Received Received
  SAT-480 Histological severity is related to cardiovascular events in lean but not in overweight and obese subjects with NAFLD Alexandra Feldman Received Received
  FRI-481 Persistent improvement of liver function tests and health-related quality of life from an individualized exercise program in patients with histological confirmed NAFLD - the HELP study Yvonne Huber Received Received
  THU-481 Impact of Proprotein Convertase Subtilisin/Kexin Type 7 genetic variation in patients with Non-Alcoholic Fatty Liver Disease Paola Dongiovanni Received Received
  SAT-481 Characterization of Patients with Both Alcoholic and Nonalcoholic Fatty Liver Disease (BAFLD) in a Large United States Cohort Naim Alkhouri Received Received
  SAT-482 Increased gut permeability is associated with oxidative stress in patients with NAFLD Francesco Baratta Received Received
  SAT-483 Increasing Trend forHepatocellular Carcinoma (HCC) Linked to Nonalcoholic Fatty Liver Disease(NAFLD) in the United States Ethan Miller Received Received
  THU-483 Discovery of Inhibitors of NLRP3 Inflammasome Assembly for the Treatment of NASH and Liver Fibrosis Davide Povero Received Received
  THU-484 Four-and-a-half LIM-Domain Protein (FHL2) affects diet induced (hepatic) steatosis and lipid droplet formation Judith Sommer Received Received
  SAT-484 Non-alcoholic fatty liver disease in non-obese young adults Yaakov Maor Received Received
  SAT-485 Risk factors for development of severe liver disease in more than 400 000 patients with type 2 diabetes: a population-based cohort study Karl Björkström Received Received
  FRI-485 Safety,Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Liver-Targeting ACC Inhibitor (PF-05221304) Following Single and Multiple Oral Doses Arthur Bergman Received Received
  THU-485 Hepatic effects of NS-0200 (Leucine-Metformin-Sildenafil) in an obese mouse model of diet-induced and biopsy-confirmed NASH Michael Zemel Received Received
  FRI-486 Regular Aspirin Use Is Not Protective Against Advanced Fibrosis in Type-2 Diabetics with Biopsy-Proven Nonalcoholic Fatty Liver Disease Amandeep Singh Received Received
  SAT-486 Multidisciplinary intervention on lifestyle improves the management of patients with nonalcoholic fatty liver disease Sara Policarpo Received Received
  THU-486 Comorbidity-specific augmented hepatic injury in a murine model of obesity-induced NAFLD and peritoneal sepsis Paul Horn Received Received
  THU-487 The anti-inflammatory and anto-fibrogenic effects of namodenoson in NAFLD/NASH animal models Shira Cohen Received Received
  SAT-487 Long-term Associations between Non-High Density Lipoprotein Cholesterol and Apolipoprotein B in Young Adulthood and Subclinical Atherosclerosis in Persons with Nonalcoholic Fatty Liver Disease in Middle Age: The CARDIA Study Lisa VanWagner Received Received
  SAT-488 Association of Nonalcoholic Fatty Liver Disease with Changes in Left Ventricular Structure and Function: The Coronary Artery Risk Development in Young Adults (CARDIA) Study Lisa VanWagner Received Received
  THU-488 Histopathologic assessment of fatty liver progression in a rodent model of chronic intake of high-fat diet, ethanol or both Carolina Guzman Received Received
  THU-489 Nicotinamide, not N1 methylnicotinamide, ameliorates hepatic steatosis via NAD-depended sirtuin activation Shusuke Morizono Received Received
  SAT-489 Investigating the Relationship Between Rare Genetic Variants and Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease Julia Wattacheril Received Received
  FRI-489 Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects Nathalie Adda Received Received
  THU-490 Elafibranor and obeticholic acid differentially alter NASH and lipid metabolism in diet-induced NASH mouse and hamster models Francois Briand Received Received
  FRI-491 Improvement of liver steatosis achieved byprobiotics in patients with nonalcoholic fatty liver disease Ionel Copaci Received Received
  SAT-491 Mixed hepatic iron deposition but not serum ferritin is associated with the presence of nonalcoholic steatohepatitis (NASH) Elena Buzzetti Received Received
  FRI-492 Endoscopic sleeve gastroplasty improves liver enzymes and hepatic steatosis index Sonal Kumar Received Received
  THU-492 CD4+ RORgt+ T cells, CD4+ T-bet+ T cells, CD4+ CD25+ Foxp3+ T cells and CD8+ T cells are differentially altered in liver and adipose tissue of mice fed a high-fat high-fructose diet in a time-dependent manner Mikhail Van Herck Received Received
  SAT-493 Do patients with abnormal liver tests and nonalcoholic fatty liver disease get statins even when indicated? Sonal Kumar Received Received
  FRI-493 Effects of Rosuvastatin and PioglitazoneLong Therapy on NASH and Coronary Heart Disease courses Nataliya Virstyuk Received Received
  SAT-494 The effect of microvascular complications of diabetes on advanced fibrosis in nonalcoholic fatty liver disease Sonal Kumar Received Received
  FRI-494 Correction of intrahepatic microcirculation disorders by L-ornithine-L-aspartate at the chronic liver diseases patients Tatiana Ermolova Received Received
  FRI-495 The anti-fibrotic agent, tipelukast (MN-001) reduces serum triglyceride significantly in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease patients with hypertriglyceridemia after 4 weeks of treatment, an interim analysis of ongoing clin Kazuko Matsuda Received Received
  THU-495 LXR inverse agonists inhibit de novo lipogenesis and reduce intestinal lipid and cholesterol absorption in a NAFLD mouse model Claus Kremoser Received Received
  SAT-495 Associations between Sarcopenia and Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in the United States Karn Wijarnpreecha Received Received
  SAT-496 The Platelet Count is Declining in American Adults in Parallel with an Increase in Risk Factors for Nonalcoholic Fatty Liver Disease Amandeep Singh Received Received
  FRI-496 Lifestyle Intervention is effective in treating non-alcoholic fatty liver disease in morbidly obese patients Simon Hohenester Received Received
  THU-496 Maternal obesity programs offspring s liver immune cells intra-uterine Jude Oben Received Received
  SAT-497 Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease Daniel Zaldumbide Received Received
  THU-497 Elafibranor restores lipogenic gene expression in a human skin stem cell-derived non-alcoholic fatty liver disease (NAFLD) model Joost Boeckmans Received Received
  SAT-498 The relationship between NAFLD and breast cancer: High prevalence and poor prognosis. Young-Sun Lee Received Received
  THU-498 The interplay between liver and muscle begins much earlier than cirrhosis. A diet-induced animal model FRANCESCA MARIA TROVATO Received Received
  THU-499 Hyperreactivity to vasoconstrictors in a rat model of non-alcoholic fatty liver disease Denise van der Graaff Received Received
  SAT-499 Impact of duodenal-jejunal bypass liner on non-alcoholic fatty liver disease Thomas Karlas Received Received
  FRI-499 s-ademetionine effectively prevents drug-induced liver injury in overweight patients with acute leukemia Igor Skrypnyk Received Received
  THU-500 Role of mitofusin-2 in NAFLD and targeting by miRNAs André Simão Received Received
  FRI-500 Drug exposure and risk of Acute Liver Failure leading to registration for liver Transplantation (ALFT): Results of the SALT III study in adults in France Dominique Larrey Received Received
  SAT-500 Nonalcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes: A prospective cohort study Won Kim Received Received
  SAT-501 Plasma cells in non-alcoholic steatohepatitis correlates with disease activity Mehul Lamba Received Received
  FRI-501 Long-Term Liver Safety of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia: Three-Year Data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER) Dominique Larrey Received Received
  SAT-502 Cardiovascular risk factors and fibrosisseverity in NAFLD: is there a link? Davide Roccarina Received Received
  FRI-502 Proof-of-concept of full-length genome sequencing as diagnostic tool of acute viral hepatitis Isaac Ruiz Received Received
  FRI-503 MH cells in combination with proteomics identify a potential biomarker for Drug-induced Liver Injury by Diclofenac Daniel Zaldumbide Received Received
  SAT-503 Prevalence, severity and patterns of clinicalpractice in outpatient visits for suspected NAFLD – the German CONSTANS STUDY Jörn Schattenberg Received Received
  FRI-504 Health care utilisation in spontaneous survivors of acute liver failure. Mhairi Donnelly Received Received
  SAT-504 Analyze of ballooning biomarker in patients with non-alcoholic steatohepatitis: A multicenter study. Yuji Ogawa Received Received
  THU-504 The changing profile of extracellular vesicles in non-alcoholic fatty liver disease progression and their role in signalling to hepatocytes Linda Ban Received Received
  THU-505 RIP3-dependent signalling contributes to non-alcoholic fatty liver disease-related hepatocarcinogenesis Marta B. Afonso Received Received
  FRI-505 Amatoxin poisoning in Germany – important clues for clinical practice Bernhard Schlevogt Received Received
  SAT-505 Health-related quality of life correlates with histological severity in non-alcoholic fatty liver disease Yvonne Huber Received Received
  THU-506 NAFLD in HIV Mono-infection is a consequence of insulin resistance but not bacterial translocation. James Maurice Received Received
  FRI-506 Opal, but not MARS improves patients albumin binding function measured by Electron Spin Resonance (ESR) in a prospective multicenter trial Daniel Zaldumbide Received Received
  SAT-506 Influence of non-alcoholic fatty liver disease on cardiovascular risk in patients with stable coronary heart disease Iryna Vakalyuk Received Received
  SAT-507 Metabolically unhealthy status impacts on the risk of significant liver injury in biopsy-proven NAFLD patients beyond obesity Javier Ampuero Received Received
  THU-507 Hepatic steatosis potentiates irinotecan-induced hepatocellular injury via dysregulation of irinotecan-metabolizing enzymes Abdo Mahli Received Received
  FRI-508 Acute Liver Failure-Organ Failure (ALF-OF) score is better than King´s College Hospital criteria in predicting mortality in patients with non-paracetamol-related acute liver failure (ALF). Francesco Figorilli Received Received
  SAT-508 Clinical Outcomes in biopsy-proven NAFLD Patients from the HEPAmet Spanish Registry. Javier Ampuero Received Received
  FRI-509 Drug Induced Liver Injury - A study on the factors affecting severity and prognosis with special emphasis on metabolic syndrome Sandeep Narayanan Received Received
  THU-509 Epigenetic modification ofurea cycle enzymes (UCE) in NAFLD animal models and patients:Implications for novel therapeutic approaches Francesco De Chiara Received Received
  SAT-509 Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in Patienst with Advanced Fibrosis/Compensated Cirrhosis Salvatore Petta Received Received
  THU-510 Ammonia:A novel target for the prevention of NAFLD progression in NASH Francesco De Chiara Received Received
  FRI-510 Serum CXCL10, CXCL11, CXCL12 and CXCL14 chemokine patterns in patients with acute liver injury Arnaud CHALIN Received Received
  SAT-510 A Comprehensive Assessment of Serial Transient elastography in various Liver disease Etiologies at the Toronto Liver Centre (CASTLE-TLC) Kerstina Boctor Received Received
  SAT-511 Predisposition to diabetes is related to insulin resistance in NAFLD patients and to decreased insulin secretion in HCV patients. Amalia Gastaldelli Received Received
  FRI-511 The proportion of patients waitlisted for transplantation for HDS induced liver injury is increasing and differs by race Joseph Odin Received Received
  THU-511 During aging osteopontin deficiency increases vulnerability to non-alcoholic fatty liver disease progression and the associated extrahepatic metabolic complications Beatriz Gómez Santos Received Received
  THU-512 Discovery and validation of new modulators of necroptosis using phenotypic high throughput screening of a large compound library Hugo Miguel de Sousa Brito Received Received
  FRI-512 Hepatic and renal tolerance of immune checkpoint inhibitors for cancer treatment: a retrospective monocentric cohort study Lucia Parlati Received Received
  SAT-513 Saturated fat is more metabolically harmful for the human liver than polyunsaturated fat or simple sugars Panu Luukkonen Received Received
  THU-513 Pharmacological inhibition of myeloperoxidase attenuates non-alcoholic steatohepatitis-induced liver fibrosis in mice Anja Koop Received Received
  FRI-513 Impact of early corticosteroid treatment in patients with indeterminate acute severe hepatitis Elisabeth Mohr Received Received
  SAT-514 Low-moderate alcohol use is associated with a lower prevalence of non-alcoholic fatty liver disease in Hispanics/Latinos living in the US: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) Aynur Unalp-Arida Received Received
  FRI-514 Evaluation of the hepatoprotective effects of Polygonum Multiflorum Thunb in Acetaminophen induced liver injury Amarzaya Chagnaadorj Received Received
  THU-514 Angiopoietin-like protein 8 is a novel vitamin D receptor-targeted lipogenic gene associated with non-alcoholic fatty liver Carmelo García-Monzón Received Received
  SAT-515 Even modest alcohol use is associated with greater steatosis on magnetic resonance imaging in patients with NAFLD - a pilot study Veeral Ajmera Received Received
  FRI-515 Prophylactic use of entecavir for lymphoma patients with past HBV infection: a randomized controlled trial Wei Ping Liu Received Received
  SAT-516 Role of nutritional intake on clinical presentation of lean and overweight NAFLD Rosa Lombardi Received Received
  THU-516 Targeting the NAFLD metabolome and the shaping of precision medicine for patients with NASH Marta Iruarrizaga-Lejarreta Received Received
  FRI-516 Inhibition of pyruvate dehydrogenase complex and lactate dehydrogenase for therapy of acute liver failure Rosa Ferriero Received Received
  FRI-517 Pyrrolizidine alkaloid-induced hepatic sinusoidal obstructive syndrome: clinical characteristics, imaging signs and pathological findings Yuhu Song Received Received
  SAT-517 Non-alcoholic fatty liver disease is omega-6 fatty acids diet dipendent in a group of obese children Anna Mantovani Received Received
  THU-517 The Pathophysiological Significance of Nerve Growth Factor in Non-alcoholic Fatty Liver Disease via FXR upregulation MING-SHIAN TSAI Received Received
  THU-518 Modulation of the NLRP3 inflammasome pathway mediates the anti-inflammatory action of indoleamine dioxygenase in experimental NASH Benedetta Piombanti Received Received
  FRI-518 Low Serum Hepcidin and High Transferrin Saturation are Associated with a Poor Short-term Survival in Adults with Acute Liver Failure Igor Spivak Received Received
  THU-519 The role of dendritic cells in different stages of non-alcoholic fatty liver disease Nahúm Méndez Received Received
  SAT-519 Change of microbiota in patients with improved fatty liver and obesity Sang Bong Ahn Received Received
  FRI-519 43 candidate SNPs were not found to be associated with drug induced liver injury Lili Pang Received Received
  SAT-520 Role of L-carnitine in pathogenesis of the atherogenic dyslipidemia in ischemic heart disease with concominent nonalcoholic steatohepatitis Igor Skrypnyk Received Received
  THU-521 Partial hepatectomyand hemodynamics: insights fromnumerical modeling on vascular response Dirk Drasdo Received Received
  SAT-521 Assessment of Baseline Hepatitis B Virus (HBV) Immunity and HBV Vaccine Responses in Prospectively Vaccinated Adults with Non Alcoholic Fatty Liver Disease (NAFLD) Carla Coffin Received Received
  SAT-522 Clinical Characteristics and Epidemiology of Patients with Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis in a Large Community-Based Healthcare Delivery System in the U.S. Heather Patton Received Received
  FRI-523 Independent cohort validation of hepatic metabolism, daily dose and comorbidities as features associated with delayed symptom onset in drug-induced liver injury Raul J. Andrade Received Received
  SAT-523 Sex hormone binding globulin levels are increased in HIV-infected men and are independently associated with lower odds of nonalcoholic fatty liver disease regardless of HIV serostatus Daniel Zaldumbide Received Received
  FRI-524 Prediction of early mortality despite Liver Transplantation in Acute Liver Failure Mariana Cardoso Received Received
  SAT-524 The Conundrum of Cryptogenic Liver Disease with Advanced Fibrosis: Poor Clinical Outcomes without Treatment Options Zobair Younossi Received Received
  SAT-525 The Worldwide Prevalence of Non-alcoholic Steatohepatitis (NASH) in Patients with Type 2 Diabetes Mellitus (DM) Zobair Younossi Received Received
  FRI-525 Should age be an absolute contraindication to Liver Transplantation in Acute Liver Failure? Mariana Cardoso Received Received
  SAT-526 Moderate Alcohol Consumption Protects Against Fatty Liver in Males Takemi Akahane Received Received
  PSO-527 Handouts Daniel Zaldumbide Received Received
  FRI-895 Poster Test Patricia Pochelon Received Received
Tel.: +34 91 736 2385
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name


The International Liver Congress 2018


11-15 April 2018 Paris

Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 20/10/2018 TO 21/04/2018
Featured Poster
Vote poster
Poster Discussion
                   DOI: 10.3252/ 

Logo Draft
Logo Cert